

10/779,784

=> d his

(FILE 'HOME' ENTERED AT 09:00:02 ON 22 AUG 2007)

FILE 'MEDLINE, EMBASE, BIOSIS, BIOTECHDS, SCISEARCH, HCAPLUS, NTIS, LIFESCI' ENTERED AT 09:00:33 ON 22 AUG 2007

L1 159646 S "5-HT"
L2 8299 S L1 (W) (AGONIST? OR STIMULAT? OR ENHANC?)
L3 81995 S MIGRAINE
L4 461 S L2 AND L3
L5 14302 S SUMATRIPTAN?
L6 192 S L4 AND L5
L7 42565 S MICROPARTICL?
L8 1 S L6 AND L7
L9 1 S L5 (W)L7
L10 192 S L4 AND L5
L11 39 S PHARMACEUTICAL AND L10
L12 73 S GLYCERYL (W) PALMITOSTEARATE?
L13 1 S L11 AND L12
L14 4 S L2 AND L7
L15 4 DUP REM L14 (0 DUPLICATES REMOVED)
L16 0 S TRIPTAN AND L12
L17 181 DUP REM L6 (11 DUPLICATES REMOVED)
L18 1 S L12 AND L17
L19 1 S L17 AND SPHERONIZ?
L20 1 S L17 AND (MACROGOL (3W) ESTER)
E MEZAACHE N/AU
L21 2 S E4
E MEZAACHE D/AU
L22 5 S E4-E5
E FRISBEE S/AU
L23 94 S E3-E12
E MAES P/AU
L24 360 S E3
L25 458 S L21 OR L22 OR L23 OR L24
L26 1 S L3 AND L25
L27 39 DUP REM L11 (0 DUPLICATES REMOVED)
L28 1 S L27 AND L7
L29 0 S SHERONIZ? AND L27
L30 1 S SPHERONIZ? AND L27

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal652mxm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 MAY 01 New CAS web site launched
NEWS 3 MAY 08 CA/CAPLUS Indian patent publication number format defined
NEWS 4 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display
fields
NEWS 5 MAY 21 BIOSIS reloaded and enhanced with archival data
NEWS 6 MAY 21 TOXCENTER enhanced with BIOSIS reload
NEWS 7 MAY 21 CA/CAPLUS enhanced with additional kind codes for German
patents
NEWS 8 MAY 22 CA/CAPLUS enhanced with IPC reclassification in Japanese
patents
NEWS 9 JUN 27 CA/CAPLUS enhanced with pre-1967 CAS Registry Numbers
NEWS 10 JUN 29 STN Viewer now available
NEWS 11 JUN 29 STN Express, Version 8.2, now available
NEWS 12 JUL 02 LEMBASE coverage updated
NEWS 13 JUL 02 LMEDLINE coverage updated
NEWS 14 JUL 02 SCISEARCH enhanced with complete author names
NEWS 15 JUL 02 CHEMCATS accession numbers revised
NEWS 16 JUL 02 CA/CAPLUS enhanced with utility model patents from China
NEWS 17 JUL 16 CAPLUS enhanced with French and German abstracts
NEWS 18 JUL 18 CA/CAPLUS patent coverage enhanced
NEWS 19 JUL 26 USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 20 JUL 30 USGENE now available on STN
NEWS 21 AUG 06 CAS REGISTRY enhanced with new experimental property tags
NEWS 22 AUG 06 BEILSTEIN updated with new compounds
NEWS 23 AUG 06 FSTA enhanced with new thesaurus edition
NEWS 24 AUG 13 CA/CAPLUS enhanced with additional kind codes for granted
patents
NEWS 25 AUG 20 CA/CAPLUS enhanced with CAS indexing in pre-1907 records

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:00:02 ON 22 AUG 2007

=> file medline embase biosis biotechds scisearch hcaplus ntis lifesci		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 09:00:33 ON 22 AUG 2007

FILE 'EMBASE' ENTERED AT 09:00:33 ON 22 AUG 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 09:00:33 ON 22 AUG 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'BIOTECHDS' ENTERED AT 09:00:33 ON 22 AUG 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'SCISEARCH' ENTERED AT 09:00:33 ON 22 AUG 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'HCAPLUS' ENTERED AT 09:00:33 ON 22 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'NTIS' ENTERED AT 09:00:33 ON 22 AUG 2007
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2007)

FILE 'LIFESCI' ENTERED AT 09:00:33 ON 22 AUG 2007
COPYRIGHT (C) 2007 Cambridge Scientific Abstracts (CSA)

=> s "5-HT"
L1 159646 "5-HT"

=> s l1 (w)(agonist? or stimulat? or enhanc?)
L2 8299 L1 (W)(AGONIST? OR STIMULAT? OR ENHANC?)

=> s migraine
L3 81995 MIGRAINE

=> s l2 and l3
L4 461 L2 AND L3

=> s sumatriptan?
L5 14302 SUMATRIPTAN?

=> s l4 and l5
L6 192 L4 AND L5

=> s microparticl?
L7 42565 MICROPARTICL?

=> s l6 and l7
L8 1 L6 AND L7

=> d ibib ab

L8 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:681407 HCAPLUS

DOCUMENT NUMBER: 141:195316
 TITLE: Rapid absorption selective 5-HT agonist formulations
 INVENTOR(S): Mezaache, Naima; Mezaache, Djelila; Frisbee, Steve; Maes, Paul
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 45 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004162333	A1	20040819	US 2004-779784	20040218
AU 2004212976	A1	20040902	AU 2004-212976	20040218
CA 2514875	A1	20040902	CA 2004-2514875	20040218
WO 2004073632	A2	20040902	WO 2004-US4572	20040218
WO 2004073632	A3	20041118		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1594470	A2	20051116	EP 2004-712297	20040218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006523620	T	20061019	JP 2006-503623	20040218
MX 2005PA08838	A	20060217	MX 2005-PA8838	20050819
NO 2005004015	A	20050916	NO 2005-4015	20050830
PRIORITY APPLN. INFO.:			US 2003-447741P	P 20030219
			WO 2004-US4572	W 20040218

AB The invention provides for a rapid absorption pharmaceutical composition comprising an effective amount of at least one selective 5-HT agonist, at least one spheronization aid and at least one solubility enhancer. The composition of the invention is incorporated into microparticles, which may be subsequently taste-masked and incorporated into a variety of dosage forms for administration to a patient suffering from migraine. Uncoated microparticles contained sumatriptan succinate 30, glyceryl palmitostearate 65, and Macrogol fatty acid esters (Gelucire 50/13) 5%.

=> d his

(FILE 'HOME' ENTERED AT 09:00:02 ON 22 AUG 2007)

FILE 'MEDLINE, EMBASE, BIOSIS, BIOTECHDS, SCISEARCH, HCAPLUS, NTIS, LIFESCI' ENTERED AT 09:00:33 ON 22 AUG 2007

L1 159646 S "5-HT"
 L2 8299 S L1 (W) (AGONIST? OR STIMULAT? OR ENHANC?)
 L3 81995 S MIGRAINE
 L4 461 S L2 AND L3
 L5 14302 S SUMATRIPTAN?
 L6 192 S L4 AND L5
 L7 42565 S MICROPARTICL?
 L8 1 S L6 AND L7

=> s 15 (w)17

L9 1 L5 (W) L7

=> d ibib ab

L9 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:385013 HCAPLUS
DOCUMENT NUMBER: 146:387123
TITLE: Microparticles with modified release of at least one
active principle and oral galenic form comprising same
INVENTOR(S): Dargelas, Frederic; Guimberteau, Florence; Castan,
Catherine; Meyrueix, Remi; Soula, Gerard
PATENT ASSIGNEE(S): Flamel Technologies, Fr.
SOURCE: PCT Int. Appl., 50pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007036671	A2	20070405	WO 2006-FR50944	20060927
WO 2007036671	A3	20070524		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

FR 2891459 A1 20070406 FR 2005-52985 20050930

PRIORITY APPLN. INFO.: FR 2005-52985 A 20050930

AB The invention concerns microparticle systems with modified release of oral active principle(s). The invention aims at providing a novel multimicroparticle galenic system operating in accordance with a dual time-dependent and pH-dependent release mechanism, which enables the following three parameters to be adjusted independently of one another: (a) the latent period preceding the release of the active principle in the stomach; (b) the pH triggering the release of the active principle in the intestine; (c) the release speed of the active principle. This is achieved through the use of coated microparticles made from particles of active principle each coated with two coating films A and B. Film A comprises: film-forming (co)polymer (A1) insol. in fluids of the gastrointestinal tract, Et cellulose (co)polymer (A2) soluble in fluids of the gastrointestinal tract, plasticizing polyvinylpyrrolidone (A3), and castor oil and optionally a surfactant and/or magnesium stearate lubricant (A4). Film B comprises a hydrophilic polymer (B1) bearing ionized groups with neutral pH (Eudragit L100-55) and a hydrophobic compound (B2) (Lubritab). Metformin hydrochloride and povidone were dissolved in water and spray-dried over neutral microspheres. The microspheres were then coated to obtain prolonged-release metformin microparticles.

=> d his

(FILE 'HOME' ENTERED AT 09:00:02 ON 22 AUG 2007)

FILE 'MEDLINE, EMBASE, BIOSIS, BIOTECHDS, SCISEARCH, HCAPLUS, NTIS, LIFESCI' ENTERED AT 09:00:33 ON 22 AUG 2007

L1 159646 S "5-HT"
 L2 8299 S L1 (W) (AGONIST? OR STIMULAT? OR ENHANC?)
 L3 81995 S MIGRAINE
 L4 461 S L2 AND L3
 L5 14302 S SUMATRIPTAN?
 L6 192 S L4 AND L5
 L7 42565 S MICROPARTICL?
 L8 1 S L6 AND L7
 L9 1 S L5 (W) L7

=> s l4 and l5

L10 192 L4 AND L5

=> s pharmaceutical and l10

L11 39 PHARMACEUTICAL AND L10

=> s glyceryl (w) palmitostearate?

L12 73 GLYCERYL (W) PALMITOSTEARATE?

=> s l11 and l12

L13 1 L11 AND L12

=> d ibib ab

L13 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:681407 HCAPLUS

DOCUMENT NUMBER: 141:195316

TITLE: Rapid absorption selective 5-HT
 agonist formulations

INVENTOR(S): Mezaache, Naima; Mezaache, Djelila; Frisbee, Steve;
 Maes, Paul

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 45 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004162333	A1	20040819	US 2004-779784	20040218
AU 2004212976	A1	20040902	AU 2004-212976	20040218
CA 2514875	A1	20040902	CA 2004-2514875	20040218
WO 2004073632	A2	20040902	WO 2004-US4572	20040218
WO 2004073632	A3	20041118		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1594470	A2	20051116	EP 2004-712297	20040218
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006523620	T	20061019	JP 2006-503623	20040218
MX 2005PA08838	A	20060217	MX 2005-PA8838	20050819
NO 2005004015	A	20050916	NO 2005-4015	20050830
PRIORITY APPLN. INFO.:			US 2003-447741P	P 20030219
			WO 2004-US4572	W 20040218

AB The invention provides for a rapid absorption pharmaceutical composition comprising an effective amount of at least one selective 5-

HT agonist, at least one spheronization aid and at least one solubility enhancer. The composition of the invention is incorporated into microparticles, which may be subsequently taste-masked and incorporated into a variety of dosage forms for administration to a patient suffering from migraine. Uncoated microparticles contained sumatriptan succinate 30, glyceryl palmitostearate 65, and Macrogol fatty acid esters (Gelucire 50/13) 5%.

=> d his

(FILE 'HOME' ENTERED AT 09:00:02 ON 22 AUG 2007)

FILE 'MEDLINE, EMBASE, BIOSIS, BIOTECHDS, SCISEARCH, HCAPLUS, NTIS, LIFESCI' ENTERED AT 09:00:33 ON 22 AUG 2007

```
L1      159646 S "5-HT"
L2      8299 S L1 (W) (AGONIST? OR STIMULAT? OR ENHANC?)
L3      81995 S MIGRAINE
L4      461 S L2 AND L3
L5      14302 S SUMATRIPTAN?
L6      192 S L4 AND L5
L7      42565 S MICROPARTICL?
L8      1 S L6 AND L7
L9      1 S L5 (W)L7
L10     192 S L4 AND L5
L11     39 S PHARMACEUTICAL AND L10
L12     73 S GLYCERYL (W) PALMITOSTEARATE?
L13     1 S L11 AND L12
```

=> s s l2 and l7

MISSING OPERATOR S L2

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s l2 and l7

L14 4 L2 AND L7

=> dup rem l14

PROCESSING COMPLETED FOR L14

L15 4 DUP REM L14 (0 DUPLICATES REMOVED)

=> d 1-4 ibib ab

L15 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:788512 HCAPLUS

DOCUMENT NUMBER: 147:197338

TITLE: Salts of potassium ATP channel openers and uses thereof

INVENTOR(S): Cowen, Neil M.; Kashkin, Kenneth B.; Yamout, Khaled A.

PATENT ASSIGNEE(S): Essentialis, Inc., USA

SOURCE: PCT Int. Appl., 245pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007081521	A2	20070719	WO 2006-US48711	20061220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,				

KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2007191351 A1 20070816 US 2006-614044 20061220
 PRIORITY APPLN. INFO.: US 2006-756941P P 20060105
 US 2006-854740P P 20061027

AB Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiolog., metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.

L15 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:83392 HCAPLUS

DOCUMENT NUMBER: 146:163111

TITLE: Pyrazolines as antiaddictive agents ad their preparation, and pharmaceutical active substance combination

INVENTOR(S): Buschmann, Helmut H.

PATENT ASSIGNEE(S): Laboratorios del Dr. Esteve, S. A., Spain

SOURCE: PCT Int. Appl., 76pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007009691	A2	20070125	WO 2006-EP6965	20060715
WO 2007009691	A3	20070308		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

EP 1749525 A1 20070207 EP 2005-384009 20050715
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU

PRIORITY APPLN. INFO.: EP 2005-384009 A 20050715
 US 2005-705483P P 20050805

OTHER SOURCE(S): MARPAT 146:163111

AB The invention relates to an active substance combination comprising at least one substituted pyrazoline compound of formula I, and at least one anti-addictive compound, a medicament comprising said active substance combination, a pharmaceutical formulation comprising said active substance

combination and the use of said active substance combination for the manufacture of a medicament. Compds. of formula I wherein R1 and R2 are independently (un)substituted Ph; R3 is (un)substituted (un)saturated (hetero)cyclyl, (un)substituted phenyl; and their stereoisomers, enantiomers, diastereoisomer, racemates, mixture of stereoisomer, mixture of diastereoisomers, mixture of enantiomers, pharmaceutically acceptable salts, solvates and N-oxides, thereof, are claimed. Example compound II was prepared by condensation of 4-chlorobenzaldehyde with Et pyruvate; the resulting trans-4-(4-chlorophenyl)-2-oxo-3-butenic acid underwent cyclization with 2,4-dichlorophenylhydrazine hydrochloride to give 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydropyrazole-3-carboxylic acid, which underwent chlorination to give the corresponding acid chloride, which underwent amidation with 1-aminopiperidine to give compound II. All the invention compds. were evaluated for their CB1 and CB2 receptor affinity. From the assay, it was determined that compound II exhibited 93 % inhibition at 10⁻⁶ M concentration and a Ki value of < 25 nM against CB1, and 33 % inhibition (10⁻⁶ M) and > 1000 nM against CB2.

L15 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:469354 HCAPLUS

DOCUMENT NUMBER: 144:474945

TITLE: Taste-masked pharmaceutical compositions comprising water-insol. polymer and a pore-former prepared by coacervation

INVENTOR(S): Lai, Jin-Wang; Qian, Ken Kangyi; Venkatesh, Gopi M.

PATENT ASSIGNEE(S): Eurand Pharmaceuticals Ltd., USA

SOURCE: U.S. Pat. Appl. Publ., 15 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006105038	A1	20060518	US 2005-213266	20050826
AU 2005307052	A1	20060526	AU 2005-307052	20051013
CA 2585363	A1	20060526	CA 2005-2585363	20051013
WO 2006055142	A2	20060526	WO 2005-US37084	20051013
WO 2006055142	A3	20060720		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1809251	A2	20070725	EP 2005-851221	20051013
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRIORITY APPLN. INFO.:				
			US 2004-627525P	P 20041112
			US 2005-213266	A 20050826
			WO 2005-US37084	W 20051013

AB There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredients, rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates rapidly with saliva in the buccal cavity forming a smooth, easy-to-swallow suspension. Furthermore, the

microparticles (crystals, granules, beads or pellets containing one or more actives) with a taste-masking membrane applied by a modified solvent coacervation process comprising a water-insol. polymer and at least one gastrosol. inorg. or organic pore-former, exhibit a pleasant taste when placed in the oral cavity and provide rapid, substantially-complete release of the dose on entry into the stomach. Thus, microgranules were prepared containing cetirizine hydrochloride hydrochlororide 20 %, microcryst. cellulose 70 % and Methocel K100LV at 10 % were granulated. The microgranules (700 mg) obtained above were microencapsulated using ethylcellulose 300 g and calcium carbonate 150 g.

L15 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:681407 HCAPLUS
DOCUMENT NUMBER: 141:195316
TITLE: Rapid absorption selective 5-HT agonist formulations
INVENTOR(S): Mezaache, Naima; Mezaache, Djelila; Frisbee, Steve; Maes, Paul
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 45 pp. .
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004162333	A1	20040819	US 2004-779784	20040218
AU 2004212976	A1	20040902	AU 2004-212976	20040218
CA 2514875	A1	20040902	CA 2004-2514875	20040218
WO 2004073632	A2	20040902	WO 2004-US4572	20040218
WO 2004073632	A3	20041118		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1594470	A2	20051116	EP 2004-712297	20040218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006523620	T	20061019	JP 2006-503623	20040218
MX 2005PA08838	A	20060217	MX 2005-PA8838	20050819
NO 2005004015	A	20050916	NO 2005-4015	20050830
PRIORITY APPLN. INFO.:			US 2003-447741P	P 20030219
			WO 2004-US4572	W 20040218

AB The invention provides for a rapid absorption pharmaceutical composition comprising an effective amount of at least one selective 5-HT agonist, at least one spheronization aid and at least one solubility enhancer. The composition of the invention is incorporated into microparticles, which may be subsequently taste-masked and incorporated into a variety of dosage forms for administration to a patient suffering from migraine. Uncoated microparticles contained sumatriptan succinate 30; glyceryl palmitostearate 65, and Macrogol fatty acid esters (Gelucire 50/13) 5%.

=> d his

(FILE 'HOME' ENTERED AT 09:00:02 ON 22 AUG 2007)

FILE 'MEDLINE, EMBASE, BIOSIS, BIOTECHDS, SCISEARCH, HCAPLUS, NTIS, LIFESCI' ENTERED AT 09:00:33 ON 22 AUG 2007

L1 159646 S "5-HT"
L2 8299 S L1 (W) (AGONIST? OR STIMULAT? OR ENHANC?)
L3 81995 S MIGRAINE
L4 461 S L2 AND L3
L5 14302 S SUMATRIPTAN?
L6 192 S L4 AND L5
L7 42565 S MICROPARTICL?
L8 1 S L6 AND L7
L9 1 S L5 (W) L7
L10 192 S L4 AND L5
L11 39 S PHARMACEUTICAL AND L10
L12 73 S GLYCERYL (W) PALMITOSTEARATE?
L13 1 S L11 AND L12
L14 4 S L2 AND L7
L15 4 DUP REM L14 (0 DUPLICATES REMOVED)

=> s triptan and l12

L16 0 TRIPTAN AND L12

=> dup rem l6

PROCESSING COMPLETED FOR L6

L17 181 DUP REM L6 (11 DUPLICATES REMOVED)

=> s l12 and l17

L18 1 L12 AND L17

=> d ibib

L18 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:681407 HCAPLUS

DOCUMENT NUMBER: 141:195316

TITLE: Rapid absorption selective 5-HT
agonist formulations

INVENTOR(S): Mezaache, Naima; Mezaache, Djelila; Frisbee, Steve;
Maes, Paul

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 45 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004162333	A1	20040819	US 2004-779784	20040218
AU 2004212976	A1	20040902	AU 2004-212976	20040218
CA 2514875	A1	20040902	CA 2004-2514875	20040218
WO 2004073632	A2	20040902	WO 2004-US4572	20040218
WO 2004073632	A3	20041118		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1594470	A2	20051116	EP 2004-712297	20040218
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006523620	T	20061019	JP 2006-503623	20040218

MX 2005PA08838	A	20060217	MX 2005-PA8838	20050819
NO 2005004015	A	20050916	NO 2005-4015	20050830
PRIORITY APPLN. INFO.:			US 2003-447741P	P 20030219
			WO 2004-US4572	W 20040218

=> d his

(FILE 'HOME' ENTERED AT 09:00:02 ON 22 AUG 2007)

FILE 'MEDLINE, EMBASE, BIOSIS, BIOTECHDS, SCISEARCH, HCAPLUS, NTIS, LIFESCI' ENTERED AT 09:00:33 ON 22 AUG 2007

```

L1      159646 S "5-HT"
L2      8299 S L1 (W) (AGONIST? OR STIMULAT? OR ENHANC?)
L3      81995 S MIGRAINE
L4      461 S L2 AND L3
L5      14302 S SUMATRIPTAN?
L6      192 S L4 AND L5
L7      42565 S MICROPARTICL?
L8      1 S L6 AND L7
L9      1 S L5 (W) L7
L10     192 S L4 AND L5
L11     39 S PHARMACEUTICAL AND L10
L12     73 S GLYCERYL (W) PALMITOSTEARATE?
L13     1 S L11 AND L12
L14     4 S L2 AND L7
L15     4 DUP REM L14 (0 DUPLICATES REMOVED)
L16     0 S TRIPTAN AND L12
L17     181 DUP REM L6 (11 DUPLICATES REMOVED)
L18     1 S L12 AND L17

```

=> s l17 and spheroniz?

L19 1 L17 AND SPHERONIZ?

=> d ibib

L19 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:681407 HCAPLUS

DOCUMENT NUMBER: 141:195316

TITLE: Rapid absorption selective 5-HT agonist formulations

INVENTOR(S): Mezaache, Naima; Mezaache, Djelila; Frisbee, Steve; Maes, Paul

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 45 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004162333	A1	20040819	US 2004-779784	20040218
AU 2004212976	A1	20040902	AU 2004-212976	20040218
CA 2514875	A1	20040902	CA 2004-2514875	20040218
WO 2004073632	A2	20040902	WO 2004-US4572	20040218
WO 2004073632	A3	20041118		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,

	MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
EP 1594470	A2 20051116	EP 2004-712297 20040218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK		
JP 2006523620	T 20061019	JP 2006-503623 20040218
MX 2005PA08838	A 20060217	MX 2005-PA8838 20050819
NO 2005004015	A 20050916	NO 2005-4015 20050830
PRIORITY APPLN. INFO.:		US 2003-447741P P 20030219 WO 2004-US4572 W 20040218

=> d 117 170-180 ibib ab

L17 ANSWER 170 OF 181 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1997:656562 HCAPLUS
 DOCUMENT NUMBER: 127:302791
 TITLE: Pharmacological overview of new 5-HT1D receptor agonists in development for the acute treatment of migraine
 AUTHOR(S): Saxena, Pramod; Ferrari, Michel D.; De Vries, Peter; Villalon, Carlos M.
 CORPORATE SOURCE: Dep. Pharmacol., Erasmus Univ. Rotterdam, Rotterdam, Neth.
 SOURCE: Frontiers in Headache Research (1997), 6(Headache Treatment), 229-241
 CODEN: FHREE3; ISSN: 1066-8322
 PUBLISHER: Lippincott-Raven
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 AB A review, with 60 refs. The available data suggest that the pharmacodynamic properties of the new 5-HT1D receptor agonists, such as zolmitriptan, MK-462, naratriptan, BMS-180048, and alniditan, are not too different of those of sumatriptan. However, the pharmacokinetics of these drugs may offer some advantage over sumatriptan with respect to the onset of action after oral administration and, perhaps, a lower headache recurrence. The paucity of available data makes a sound assessment of their full clin. potential difficult at this time.
 REFERENCE COUNT: 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 171 OF 181 MEDLINE on STN DUPLICATE 2
 ACCESSION NUMBER: 1998028458 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 9363828
 TITLE: Emerging treatments in headache.
 AUTHOR: Diener H C; Gendolla A; Juptner M; Kaube H; Limmroth V
 CORPORATE SOURCE: Department of Neurology, University of Essen, Germany.
 SOURCE: European neurology, (1997) Vol. 38, No. 3, pp. 167-74.
 Ref: 65
 Journal code: 0150760. ISSN: 0014-3022.
 PUB. COUNTRY: Switzerland
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 199801
 ENTRY DATE: Entered STN: 6 Feb 1998
 Last Updated on STN: 6 Feb 1998
 Entered Medline: 29 Jan 1998
 AB Recent PET studies performed in humans during migraine attacks revealed a 'spreading depression-like' oligemia in the occipital cortex during the aura phase and a region of increased blood flow in the brainstem during the headache phase. Animal models were established to

test new migraine drugs. A number of 5-HT agonists, the so-called 'triptans', will be available in future besides sumatriptan to treat acute migraine attacks. Migraine prophylaxis is still hampered by the fact that we do not understand the action of drugs used for this purpose and do not have an animal model. Nevertheless, new substances were introduced recently into the prophylaxis of migraine.

L17 ANSWER 172 OF 181 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:646581 HCAPLUS

DOCUMENT NUMBER: 127:341746

TITLE: The selectivity of MDL 74,721 in models of neurogenic versus vascular components of migraine

AUTHOR(S): Petty, Margaret A.; Elands, Jack; Johnson, Michael P.; Linnik, Matthew D.; Hamel, Edith; Moskowitz, Michael A.; Lee, Won Suk; McCarty, Deborah R.; Hibert, Marcel; Baron, Bruce M.

CORPORATE SOURCE: Marion Merrell, 16 rue d'Ankara, Strasbourg, 67080; Fr.

SOURCE: European Journal of Pharmacology (1997), 336(2/3), 127-136

CODEN: EJPHAZ; ISSN: 0014-2999

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB MDL 74,721 (R)-2-(N1,N1-dipropylamino)-8-methylaminosulfonylmethyl-1,2,3,4-tetrahydronaphthalene, a sulfonamidotetralin, has been found to exhibit a 10000-fold greater potency in neurogenic vs. vascular models of migraine. Sumatriptan, a relatively pure 5-HT1D/5-HT1B receptor agonist, also showed higher potency vs. neurogenic inflammation. However, for sumatriptan, the potency difference (100-fold) in the two pathophysiol. models was less pronounced than seen for MDL 74,721. The affinity profile of MDL 74,721 at 5-HT1 receptor subtypes may in part explain its ability to differentiate these two physiol. responses. MDL 74,721 demonstrated nanomolar affinity for 5-HT1A (12.7 nM) and 5-HT1D (41.3 nM) but considerably lower affinity for 5-HT1B receptors (>1000 nM). Serotonin-like activity was seen in in vitro functional assays including inhibition of forskolin-stimulated cAMP accumulation in human 5-HT1D receptor-transfected fibroblasts or eliciting vasoconstriction in isolated human pial arteries. The intrinsic activity (relative to 5-HTEAmax) and affinity (pD2) for the human cerebrovascular 5-HT receptors were: 5-HT (100%, 7.51), sumatriptan (94%, 6.85) and MDL 74,721 (66%, 5.70). In anesthetized cats, treatment with MDL 74,721 resulted in a dose-related reduction in the percentage of carotid flow going through the arteriovenous anastomoses to the lungs, with an ED50 of 0.3 mg/kg i.v., the same as sumatriptan. However, in the guinea-pig neurogenic model, MDL 74,721 inhibited plasma protein extravasation with an ED50 of 0.023 µg/kg compared to 2.5 µg/kg for sumatriptan. MDL 74,721 was also effective in this model (in rats) after oral administration. In conclusion, MDL 74,721 demonstrates a preclin. profile consistent with anti-migraine efficacy. Its marked preference for inhibiting neurogenic inflammation makes this compound a useful tool for assessing the relative contribution of this pathophysiol. mechanism to the human disease state.

REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 173 OF 181 MEDLINE on STN DUPLICATE 3

ACCESSION NUMBER: 1998067063 MEDLINE

DOCUMENT NUMBER: PubMed ID: 9403359

TITLE: The way to serotonergic use and abuse in migraine

AUTHOR: Nicolodi M; Del Bianco P L; Sicuteri F

CORPORATE SOURCE: Interuniversity Centre of Neurochemistry and Clinical

Pharmacology of Idiopathic Headache, Florence University, Italy.

SOURCE: International journal of clinical pharmacology research, (1997) Vol. 17, No. 2-3, pp. 79-84.
Journal code: 8110183. ISSN: 0251-1649.

PUB. COUNTRY: Switzerland

DOCUMENT TYPE: (CLINICAL TRIAL)
(CONTROLLED CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199801

ENTRY DATE: Entered STN: 22 Jan 1998
Last Updated on STN: 22 Jan 1998
Entered Medline: 7 Jan 1998

AB 5-HT is currently indicated to play a role in migraine (M). Previously evidenced 5-HT supersensitivity which characterizes M is insufficient to compensate for a possible deficit in 5-HT bioavailability. Inducing a further up-regulation of 5-HT receptor can yield improvement of M syndrome. Chronic treatments of methysergide and propranolol, drugs exerting antagonist action at 5-HT receptors, induced a significant amelioration in 256M sufferers. On the contrary, chronic treatments of ergotamine and sumatriptan, both provided with a 5-HT₁ agonist activity, induced a worsening of M in 134 M sufferers. The M worsening was paralleled by an increase in consumption of analgesic drugs. Discussion concerns the effects of the chronically given 5-HT agonists and antagonists as well as the possible receptor mechanism underlying "craving for serotonin" in severe M. The increase of 5-HT supersensitivity evidenced at the end of M attacks is also discussed and its role in determining the interruption of the attack is here suggested.

L17 ANSWER 174 OF 181 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:134796 HCAPLUS

DOCUMENT NUMBER: 126:144111

TITLE: 6-Substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta[7,6-b]indoles useful as 5-HT_{1F} receptor agonists.

INVENTOR(S): Flaugh, Michael Edward; Kiefer, Anton Daniel, Jr.; Walker, Clint Duane; Xu, Yao Chang

PATENT ASSIGNEE(S): Eli Lilly and Co., USA

SOURCE: Eur. Pat. Appl., 69 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 749962	A1	19961227	EP 1996-304612	19960621
EP 749962	B1	20001102		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CA 2179678	A1	19961224	CA 1996-2179678	19960621
PRIORITY APPLN. INFO.:			US 1995-1970	A 19950623
OTHER SOURCE(S):		MARPAT 126:144111		

AB The invention provides novel agonists of the serotonin 5-HT_{1F} receptor of formula I [R₁, R₂ = H, C₁-4 alkyl, or CH₂CH₂-Aryl where Aryl = Ph, monohalophenyl, or 1-(C₁-6 alkyl)-pyrazol-4-yl; X = OH, NHC(O)R₃, NHC(:Y)NHR₄, NHCOOR₅, COR₆ or NHSO₂R₇; R₃ = C₁-6 alkyl, C₂-6 alkenyl, C₃-8 cycloalkyl, Ph, substituted Ph, naphthyl, phenylalkyl, thienylmethyl, or heterocyclyl; R₄ = C₁-6 alkyl, Ph, dihalophenyl; R₅ = C₁-6 alkyl, C₂-6 alkenyl, monohalobenzyl, monohalophenyl; R₆ = C₁-6 alkyl, Ph,

monohalophenyl, monoalkoxyphenyl; R7 = NMe2, monohalophenyl, monoalkylphenyl; m = 0 or 1; n = 1 or 2; and Y = S or O; and pharmaceutically acceptable salts and hydrates thereof, providing: X \neq OH when m = 0, n = 1, and R1 and R2 = H or C1-6 alkyl; and R3 \neq C1-6 alkyl when m = 0, n = 1, and R1 and R2 = H or C1-6 alkyl]. I are useful for a variety of purposes, and particularly in a method of inhibiting neuronal protein extravasation without causing vasoconstriction, i.e., for treatment of migraine. Approx. 115 synthetic examples and 11 formulation examples are given. For instance, 6-[(tert-butoxycarbonyl)amino]-3-(dimethylamino)-9-(triisopropylsilyl)-1,2,3,4-tetrahydro-9H-carbazole (preparation given) underwent a sequence of desilylation (83%), followed by removal of the BOC group and amidation with 4-FC6H4COCl (95%); to give title compound II. Sumatriptan and 5 other compds. were assayed against various 5-HT receptor subtypes, and for inhibition of protein extravasation in rats. The highest correlation factor with extravasation (0.94) was found for the 5-HT1F receptor subtype. I are said to show high oral bioavailability, rapid onset, long duration of action, high potency, and high selectivity for the 1F subtype, avoiding complications due to vasoconstriction (no data).

L17 ANSWER 175 OF 181 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:365215 HCAPLUS
DOCUMENT NUMBER: 127:28509
TITLE: Pharmacology of serotonin as related to anesthesia
AUTHOR(S): Gyermek, Laszlo
CORPORATE SOURCE: Department of Anesthesiology, Harbor-UCLA Medical Center, UCLA School of Medicine, Torrance, CA, USA
SOURCE: Journal of Clinical Anesthesia (1996), 8(5), 402-425
CODEN: JCLBE7; ISSN: 0952-8180
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review with 232 refs. Serotonin (5-hydroxytryptamine) is an important biogenic amine that fulfills the role of neurotransmitter and neuromodulator. It has been a focus of interest during the last decade. Its diversity of pharmacol. actions is related to a wide variety of receptors and effector mechanisms. Seven serotonin receptor families have been identified thus far. They are genetically different transmembrane proteins composed of several hundred amino acids. The majority of these are G-protein-coupled, except the 5-HT3 receptors, which are directly ligand gated to fast ion channels. Serotonin is widely distributed in the body within the central and peripheral nervous systems, smooth muscles, and platelets, in particular. Consequently, its effects manifest mainly in these organs and influence a wide variety of neural, vascular, smooth muscle, and platelet functions. (Melatonin, a physiol. active metabolite of serotonin, is also instrumental in affecting many neural and hormonal functions.). Several selective agonists and particularly many selective antagonists have been developed for serotonin, which helped the serotonin receptor subtype classification. Some of these drugs are also used therapeutically in the treatment of migraine (eg, sumatriptan, which is a 5-HT1 receptor agonist), vascular disorders (5-HT2 antagonists), and nausea and vomiting (5-HT3 antagonists, eg, dolasetron, granisetron, ondansetron, and tropisetron), and have been investigated in gastrointestinal motility disorders (5-HT4 antagonists) and behavioral psychopathologies (5-HT1 agonists and 5-HT2-4 antagonists). Serotonin reuptake inhibitors are of particular clin. importance in the treatment of psychol. illnesses. Future use of these drugs is also envisioned in the treatment of certain types of pain syndromes. Awareness of the serotonergic drugs and the recognition of possible drug interactions among drugs that influence serotonergic mechanisms in humans are becoming increasingly important in the practice of anesthesiol.

REFERENCE COUNT: 232 THERE ARE 232 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 176 OF 181 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN DUPLICATE 4

ACCESSION NUMBER: 95058916 EMBASE
DOCUMENT NUMBER: 1995058916
TITLE: [Sumatriptan: Update information on pharmacology, mechanism of action and clinical use].
SUMATRIPTAN: AKTUELLE ERKENNTNISSE ZU PHARMAKOLOGIE, WIRKUNGSMECHANISMUS UND KLINISCHEM EINSATZ.
AUTHOR: Limmroth V.; Waeber C.; Diener H.-C.
CORPORATE SOURCE: Klinik und Poliklinik für Neurologie, Universität Essen, Hufelandstr. 55, 45122 Essen, Germany
SOURCE: Aktuelle Neurologie, (1995) Vol. 22, No. 1, pp. 31-39. .
ISSN: 0302-4350 CODEN: AKNUAR
COUNTRY: Germany
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 008 Neurology and Neurosurgery
030 Pharmacology
037 Drug Literature Index
LANGUAGE: German
SUMMARY LANGUAGE: German; English
ENTRY DATE: Entered STN: 14 Mar 1995
Last Updated on STN: 14 Mar 1995

AB Sumatriptan is the first selective serotonin (5-HT) agonist, which in numerous clinical trials proved to be a potent drug in the treatment of migraine and cluster headache and received approval for these indications in several countries. It is the first anti-migraine drug to act receptor-specific and has introduced a new era of headache treatment. Initially suspected as a potent anti-migraine drug because of its ability to constrict cerebral arteries, recent evidence indicates that its beneficial effects might be due to a blockade of neurotransmitter release and neurotransmission. Besides providing the physician with another helpful tool in the treatment of headache, sumatriptan provides further insight into the pathophysiology of headache. The article reviews the current knowledge of pharmacology, mechanism and clinical trials.

L17 ANSWER 177 OF 181 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN DUPLICATE 5

ACCESSION NUMBER: 93103210 EMBASE
DOCUMENT NUMBER: 1993103210
TITLE: Focus on sumatriptan: A selective serotonin- 1 D receptor agonist for the acute treatment of migraine.
AUTHOR: Fankhauser M.P.; Wendt J.K.
CORPORATE SOURCE: Department of Pharmacy Practice, College of Pharmacy, University of Arizona, Tucson, AZ, United States
SOURCE: Hospital Formulary, (1993) Vol. 28, No. 3, pp. 247-248+250-252+254+260-261. .
ISSN: 0098-6909 CODEN: HOFOD
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 008 Neurology and Neurosurgery
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 16 May 1993
Last Updated on STN: 16 May 1993

AB Sumatriptan is a serotonin (5-HT) agonist that is highly selective for the 5-HT_{1D} receptor subtype. A subcutaneous form of the drug was recently approved by the FDA for the acute treatment of migraine attacks, with or without aura.

According to results of trials reviewed in this Focus, 70 to 80% of patients with migraine treated with subcutaneous sumatriptan reported a significant reduction of headache severity within 2 hours of administration compared with 20 to 30% of placebo recipients. The subcutaneous form of the drug has also been shown to be efficacious even when administered several hours after migraine onset. Few adverse reactions are associated with the drug's use. Migraine recurrence-reported in up to 46% of patients within 24 to 48 hours after initial response to treatment- requires further study and comparison with standard agents. Additional trials of subcutaneous sumatriptan versus standard antimigraine agents, such as ergot alkaloids, are needed to determine its efficacy and safety in the acute treatment of migraines and cluster headaches.

L17 ANSWER 178 OF 181 SCISEARCH COPYRIGHT (c) 2007 The Thomson Corporation
on STN

ACCESSION NUMBER: 1993:136764 SCISEARCH
THE GENUINE ARTICLE: KP082
TITLE: 5-HYDROXYTRYPTAMINE RECEPTOR CHARACTERIZATION OF HUMAN
CEREBRAL, MIDDLE MENINGEAL AND TEMPORAL ARTERIES -
REGIONAL DIFFERENCES
AUTHOR: JANSSEN I (Reprint); OLESEN J; EDVINSSON L
CORPORATE SOURCE: UNIV LUND, MALMO GEN HOSP, DEPT EXPTL RES, S-21401 MALMO,
SWEDEN (Reprint); GENTOFTE HOSP, DEPT NEUROMED, DK-2900
COPENHAGEN, DENMARK; UNIV LUND HOSP, DEPT INTERNAL MED,
S-22185 LUND, SWEDEN
COUNTRY OF AUTHOR: SWEDEN; DENMARK
SOURCE: ACTA PHYSIOLOGICA SCANDINAVICA, (FEB 1993) Vol. 147, No.
2, pp. 141-150.
ISSN: 0001-6772.
PUBLISHER: BLACKWELL SCIENCE LTD, OSNEY MEAD, OXFORD, OXON, ENGLAND
OX2 0EL.
DOCUMENT TYPE: Article; Journal
FILE SEGMENT: LIFE
LANGUAGE: English
REFERENCE COUNT: 53
ENTRY DATE: Entered STN: 1994
Last Updated on STN: 1994

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB We have studied the regional distribution of 5-hydroxytryptamine (5-HT) receptor subtypes in fresh circular segments of human cerebral, middle meningeal, and temporal arteries. Vasomotor responses induced by a series of 5-HT agonists and antagonists with some degree of selectivity were studied by using a sensitive in vitro system.

Nine 5-HT agonists were examined for contractile effects on the arteries. In cerebral and meningeal arteries 5-carboxamidotryptamine (5-CT) was more potent than 5-HT. The opposite order of potency (5-HT-5-CT) was found in temporal arteries. In the cerebral arteries 5-methoxytryptamine (5-MeOHT) was more potent than sumatriptan while sumatriptan was more potent than 5-MeOHT in meningeal and temporal arteries.

The 5-HT₁ receptor antagonist, methiothepin, competitively antagonized 5-CT-induced contractions in cerebral arteries, with a pA₂ value of 9.05. 5-HT-induced contractions were competitively antagonized by ketanserin (5-HT₂) in the temporal arteries pA₂ value of 9.06). Methiothepin and ketanserin had non-competitive antagonistic effects in the middle meningeal arteries. The 5-HT₃ selective antagonist ondansetron did not cause any shift of the contractions induced by 2-methyl-5-HT in the temporal, cerebral and middle meningeal arteries.

These results suggest that the cerebral arteries mainly contain 5-HT_{1D} or 5-HT₁-like receptors, and the temporal artery 5-HT₂ receptors; the data further indicate the presence of both receptor subtypes in the middle meningeal artery.

L17 ANSWER 179 OF 181 SCISEARCH COPYRIGHT (c) 2007 The Thomson Corporation
on STN

ACCESSION NUMBER: 1992:652410 SCISEARCH
THE GENUINE ARTICLE: JW566
TITLE: TREATMENT OF MIGRAINE ATTACKS WITH SUBCUTANEOUS
SUMATRIPTAN - 1ST PLACEBO-CONTROLLED STUDY
AUTHOR: VISSER W H (Reprint); FERRARI M D; BAYLISS E M; LUDLOW S;
PILGRIM A J
CORPORATE SOURCE: UNIV HOSP LEIDEN, DEPT NEUROL, POB 9600, 2300 RC LEIDEN,
NETHERLANDS; GLAXO GRP RES LTD, GREENFORD UB6 0HE, MIDDX,
ENGLAND
COUNTRY OF AUTHOR: NETHERLANDS; ENGLAND
SOURCE: CEPHALALGIA, (OCT 1992) Vol. 12, No. 5, pp. 308-313.
ISSN: 0333-1024.
PUBLISHER: SCANDINAVIAN UNIVERSITY PRESS, PO BOX 2959 TOYEN, JOURNAL
DIVISION CUSTOMER SERVICE, N-0608 OSLO, NORWAY.
DOCUMENT TYPE: Article; Journal
FILE SEGMENT: CLIN
LANGUAGE: English
REFERENCE COUNT: 29
ENTRY DATE: Entered STN: 1994
Last Updated on STN: 1994

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB The results of the very first large-scale placebo-controlled
dose-response trial with the novel selective 5-hydroxytryptaminel-like
(5HT1-like) receptor agonist sumatriptan are presented. We
studied the efficacy and tolerability of subcutaneous injections of 1 mg,
2 mg and 3 mg of sumatriptan in alleviating migraine
attacks in a double-blind, placebo-controlled, parallel-group, multicentre
clinical trial. Six-hundred and ninety patients were randomized and 685
received study medication. At 30 min, reduction of headache severity to
mild or none (primary efficacy endpoint) was achieved in 22% (95% CI:
15-28%) of placebo-treated patients and in 39% (CI: 31-46%) of patients
treated with 1 mg sumatriptan, 44% (CI: 36-51%) treated with 2
mg sumatriptan and 55% (CI: 48-63%) treated with 3 mg
sumatriptan. Differences from placebo were 17% (CI: 8-27%) for 1
mg sumatriptan, 22% (CI: 13-32%) for 2 mg sumatriptan
and 34% (CI: 24-44%) for 3 mg sumatriptan ($p < 0.001$ for all
three comparisons). Other migraine symptoms were also more
effectively treated by sumatriptan than by placebo.
Subsequently, an open-label 3 mg dose subcutaneous sumatriptan
was given to partial or non-responders. Thirty minutes after this open
dose the response rate to sumatriptan had improved to between 70
and 80%. Adverse events after sumatriptan were minor and
short-lived. We conclude that subcutaneous sumatriptan is well
tolerated in doses up to 3 +3 mg and may rapidly abort migraine
attacks.

L17 ANSWER 180 OF 181 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on
STN

ACCESSION NUMBER: 1991:8628 BIOSIS
DOCUMENT NUMBER: PREV199191008628; BA91:8628
TITLE: MECHANISM OF THE ACTION OF ANTIMIGRAINE DRUGS.
AUTHOR(S): MONTASTRUC J L [Reprint author]; SENARD J M; MONTASTRUC P
CORPORATE SOURCE: SERV PHARMACOL MEDICALE CLINIQUE, INSERM U317; CENTRE
MIDI-PYRENEES PHARMAOVIGILANCE D'INFORMATIONS SUR LE
MEDICAMENT, CENTRE HOSPITALIER UNIVERSITAIRE FACULTE
MEDECINE, 37 ALLEES JULES-GUESDE, 31073 TOULOUSE, FR
SOURCE: Circulation et Metabolisme du Cerveau, (1990) Vol. 7, No.
3, pp. 179-188.
CODEN: CMCEEW. ISSN: 0264-6900.
DOCUMENT TYPE: Article
FILE SEGMENT: BA
LANGUAGE: FRENCH

ENTRY DATE: Entered STN: 8 Dec 1990
Last Updated on STN: 30 Jan 1991

AB The mechanism of action of antimigrainous drugs remains controversial. Antimigraine drugs belong to several pharmacological: analgesic and non-steroidal antiinflammatory agents, ergot alkaloids, beta-blocking drugs... Sumatriptan, a serotonergic (5 HT) agonist, is a new drug recently shown to be effective in the migraine crisis. The discrepancies on the mechanism of action of antimigrainous drugs are explained by the lack of experimental models, definitive pathophysiological mechanisms as well as the multiple sites of action of ergot alkaloids (on alpha, 5 HT and dopamine receptors). Recent binding studies indicate that drugs used in the acute treatment could act through activation of 5 HT 1D and/or 5 HT 1A receptors. Prophylactic drugs exhibit common antagonistic properties on 5 HT 2 and/or 5 HT 1A receptors. Finally, one can suggest that antimigraine drugs act through a "final common pathway" involving 5 HT and/or noradrenergic (NA) neurons. These two aminergic hypotheses are not opposite since the relationships between 5 HT and NA neurons are well characterized. These new pharmacological investigations could lead to rational development of new drugs.

=> d his

(FILE 'HOME' ENTERED AT 09:00:02 ON 22 AUG 2007)

FILE 'MEDLINE, EMBASE, BIOSIS, BIOTECHDS, SCISEARCH, HCAPLUS, NTIS, LIFESCI' ENTERED AT 09:00:33 ON 22 AUG 2007

L1 159646 S "5-HT"
L2 8299 S L1 (W) (AGONIST? OR STIMULAT? OR ENHANC?)
L3 81995 S MIGRAINE
L4 461 S L2 AND L3
L5 14302 S SUMATRIPTAN?
L6 192 S L4 AND L5
L7 42565 S MICROPARTICL?
L8 1 S L6 AND L7
L9 1 S L5 (W) L7
L10 192 S L4 AND L5
L11 39 S PHARMACEUTICAL AND L10
L12 73 S GLYCERYL (W) PALMITOSTEARATE?
L13 1 S L11 AND L12
L14 4 S L2 AND L7
L15 4 DUP REM L14 (0 DUPLICATES REMOVED)
L16 0 S TRIPTAN AND L12
L17 181 DUP REM L6 (11 DUPLICATES REMOVED)
L18 1 S L12 AND L17
L19 1 S L17 AND SPHERONIZ?

=> s l17 and (macrogol (3w)ester)

L20 1 L17 AND (MACROGOL (3W) ESTER)

=> d ibib ab

L20 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:681407 HCAPLUS

DOCUMENT NUMBER: 141:195316

TITLE: Rapid absorption selective 5-HT
agonist formulations

INVENTOR(S): Mezaache, Naima; Mezaache, Djelila; Frisbee, Steve;
Maes, Paul

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 45 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004162333	A1	20040819	US 2004-779784	20040218
AU 2004212976	A1	20040902	AU 2004-212976	20040218
CA 2514875	A1	20040902	CA 2004-2514875	20040218
WO 2004073632	A2	20040902	WO 2004-US4572	20040218
WO 2004073632	A3	20041118		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1594470	A2	20051116	EP 2004-712297	20040218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006523620	T	20061019	JP 2006-503623	20040218
MX 2005PA08838	A	20060217	MX 2005-PA8838	20050819
NO 2005004015	A	20050916	NO 2005-4015	20050830
PRIORITY APPLN. INFO.:			US 2003-447741P	P 20030219
			WO 2004-US4572	W 20040218

AB The invention provides for a rapid absorption pharmaceutical composition comprising an effective amount of at least one selective 5-HT agonist, at least one spheronization aid and at least one solubility enhancer. The composition of the invention is incorporated into microparticles, which may be subsequently taste-masked and incorporated into a variety of dosage forms for administration to a patient suffering from migraine. Uncoated microparticles contained sumatriptan succinate 30, glyceryl palmitostearate 65, and Macrogol fatty acid esters (Gelucire 50/13) 5%.

=> e mezaache n/au

E1	1	MEZAACHE E L/AU
E2	2	MEZAACHE EL HACENE/AU
E3	0 -->	MEZAACHE N/AU
E4	2	MEZAACHE NAIMA/AU
E5	6	MEZAAL M/AU
E6	2	MEZAAL MOHAMMED A/AU
E7	5	MEZAAL T J/AU
E8	1	MEZAARRAU C/AU
E9	26	MEZABASSO L/AU
E10	1	MEZABERNARDINO H/AU
E11	8	MEZAC M/AU
E12	1	MEZACALIX A/AU

=> s e4

L21 2 "MEZAACHE NAIMA"/AU

=> e mezaache d/au

E1	2	MEZAACHE A/AU
E2	1	MEZAACHE A L/AU
E3	0 -->	MEZAACHE D/AU
E4	2	MEZAACHE DJELIL/AU
E5	3	MEZAACHE DJELILA/AU
E6	4	MEZAACHE E/AU
E7	1	MEZAACHE E L/AU
E8	2	MEZAACHE EL HACENE/AU

E9	2	MEZAACHE NAIMA/AU
E10	6	MEZAAL M/AU
E11	2	MEZAAL MOHAMMED A/AU
E12	5	MEZAAL T J/AU

=> s e4-e5

L22 5 ("MEZAACHE DJELIL"/AU OR "MEZAACHE DJELILA"/AU)

=> e frisbee s/au

E1	1	FRISBEE ROBERT HENRY/AU
E2	1	FRISBEE ROGER/AU
E3	4 -->	FRISBEE S/AU
E4	17	FRISBEE S E/AU
E5	32	FRISBEE S J/AU
E6	1	FRISBEE S M/AU
E7	1	FRISBEE S S/AU
E8	2	FRISBEE STEPHANIE/AU
E9	16	FRISBEE STEPHANIE J/AU
E10	2	FRISBEE STEVE/AU
E11	1	FRISBEE STEVEN/AU
E12	18	FRISBEE STEVEN E/AU

=> s e3-e12

L23 94 ("FRISBEE S"/AU OR "FRISBEE S E"/AU OR "FRISBEE S J"/AU OR "FRISBEE S M"/AU OR "FRISBEE S S"/AU OR "FRISBEE STEPHANIE"/AU OR "FRISBEE STEPHANIE J"/AU OR "FRISBEE STEVE"/AU OR "FRISBEE STEVEN"/AU OR "FRISBEE STEVEN E"/AU)

=> e maes p/au

E1	6	MAES OLIVIER C/AU
E2	2	MAES OLIVIER CHARLES ANTOINE/AU
E3	360 -->	MAES P/AU
E4	14	MAES P C/AU
E5	1	MAES P C J M/AU
E6	3	MAES P J/AU
E7	2	MAES PASCAL/AU
E8	2	MAES PATRICIA/AU
E9	2	MAES PATTIE/AU
E10	17	MAES PAUL/AU
E11	5	MAES PAUL J/AU
E12	5	MAES PAUL JOSE/AU

=> s e3

L24 360 "MAES P"/AU

=> d his

(FILE 'HOME' ENTERED AT 09:00:02 ON 22 AUG 2007)

FILE 'MEDLINE, EMBASE, BIOSIS, BIOTECHDS, SCISEARCH, HCAPLUS, NTIS, LIFESCI' ENTERED AT 09:00:33 ON 22 AUG 2007

L1	159646 S	"5-HT"
L2	8299 S L1 (W)	(AGONIST? OR STIMULAT? OR ENHANC?)
L3	81995 S	MIGRAINE
L4	461 S L2 AND L3	
L5	14302 S	SUMATRIPTAN?
L6	192 S L4 AND L5	
L7	42565 S	MICROPARTICL?
L8	1 S L6 AND L7	
L9	1 S L5 (W)	L7
L10	192 S L4 AND L5	
L11	39 S	PHARMACEUTICAL AND L10
L12	73 S	GLYCERYL (W) PALMITOSTEARATE?
L13	1 S	L11 AND L12

L14 4 S L2 AND L7
 L15 4 DUP REM L14 (0 DUPLICATES REMOVED)
 L16 0 S TRIPTAN AND L12
 L17 181 DUP REM L6 (11 DUPLICATES REMOVED)
 L18 1 S L12 AND L17
 L19 1 S L17 AND SPHERONIZ?
 L20 1 S L17 AND (MACROGOL (3W)ESTER)
 E MEZAACHE N/AU
 L21 2 S E4
 E MEZAACHE D/AU
 L22 5 S E4-E5
 E FRISBEE S/AU
 L23 94 S E3-E12
 E MAES P/AU
 L24 360 S E3

=> s l21 or l22 or l23 or l24

L25 458 L21 OR L22 OR L23 OR L24

=> s l3 and l25

L26 1 L3 AND L25

=> d ibib ab

L26 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:681407 HCAPLUS

DOCUMENT NUMBER: 141:195316

TITLE: Rapid absorption selective 5-HT agonist formulations

INVENTOR(S): Mezaache, Naima; Mezaache, Djelila

; Frisbee, Steve; Maes, Paul

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 45 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004162333	A1	20040819	US 2004-779784	20040218
AU 2004212976	A1	20040902	AU 2004-212976	20040218
CA 2514875	A1	20040902	CA 2004-2514875	20040218
WO 2004073632	A2	20040902	WO 2004-US4572	20040218
WO 2004073632	A3	20041118		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1594470	A2	20051116	EP 2004-712297	20040218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006523620	T	20061019	JP 2006-503623	20040218
MX 2005PA08838	A	20060217	MX 2005-PA8838	20050819
NO 2005004015	A	20050916	NO 2005-4015	20050830
PRIORITY APPLN. INFO.:			US 2003-447741P	P 20030219
			WO 2004-US4572	W 20040218

AB The invention provides for a rapid absorption pharmaceutical composition
 comprising an effective amount of at least one selective 5-HT agonist, at
 least one spheronization aid and at least one solubility enhancer. The
 composition

of the invention is incorporated into microparticles, which may be subsequently taste-masked and incorporated into a variety of dosage forms for administration to a patient suffering from migraine. Uncoated microparticles contained sumatriptan succinate 30, glyceryl palmitostearate 65, and Macrogol fatty acid esters (Gelucire 50/13) 5%.

=> d his

(FILE 'HOME' ENTERED AT 09:00:02 ON 22 AUG 2007)

FILE 'MEDLINE, EMBASE, BIOSIS, BIOTECHDS, SCISEARCH, HCAPLUS, NTIS, LIFESCI' ENTERED AT 09:00:33 ON 22 AUG 2007

L1 159646 S "5-HT"
L2 8299 S L1 (W) (AGONIST? OR STIMULAT? OR ENHANC?)
L3 81995 S MIGRAINE
L4 461 S L2 AND L3
L5 14302 S SUMATRIPTAN?
L6 192 S L4 AND L5
L7 42565 S MICROPARTICL?
L8 1 S L6 AND L7
L9 1 S L5 (W) L7
L10 192 S L4 AND L5
L11 39 S PHARMACEUTICAL AND L10
L12 73 S GLYCERYL (W) PALMITOSTEARATE?
L13 1 S L11 AND L12
L14 4 S L2 AND L7
L15 4 DUP REM L14 (0 DUPLICATES REMOVED)
L16 0 S TRIPTAN AND L12
L17 181 DUP REM L6 (11 DUPLICATES REMOVED)
L18 1 S L12 AND L17
L19 1 S L17 AND SPHERONIZ?
L20 1 S L17 AND (MACROGOL (3W) ESTER)
E MEZAACHE N/AU
L21 2 S E4
E MEZAACHE D/AU
L22 5 S E4-E5
E FRISBEE S/AU
L23 94 S E3-E12
E MAES P/AU
L24 360 S E3
L25 458 S L21 OR L22 OR L23 OR L24
L26 1 S L3 AND L25

=> dup rem l11

PROCESSING COMPLETED FOR L11

L27 39 DUP REM L11 (0 DUPLICATES REMOVED)

=> d 1-39 ibib ab

L27 ANSWER 1 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:702698 HCAPLUS

DOCUMENT NUMBER: 147:125811

TITLE: Combination comprising cyclooxygenase and lipooxygenase inhibitor for managing inflammation and associated disorders

INVENTOR(S): Jain; Rajesh; Jindal, Kour Chand

PATENT ASSIGNEE(S): Panacea Biotec Ltd., India

SOURCE: PCT Int. Appl., 37pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007072503	A2	20070628	WO 2006-IN496	20061218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: IN 2005-DE3431 A 20051221

AB This invention relates to pharmaceutical compns. comprising at least one analgesic and anti-inflammatory compound(s) that inhibits both cyclooxygenase (COX) and lipooxygenase (LOX) as active agent in combination with at least one another active agent(s) optionally with other pharmaceutically, acceptable excipients is provided. Also described are process for preparation of such compns. and method of using such compns. for the management of inflammation and pain and/or other associated disorders. Thus, tablet was prepared containing licofelone 200 mg, nimesulide 100 mg, AvicelPH 101 50 mg, lactose monohydrate 35 mg, starch 1500 30 mg, sodium lauryl sulfate 20 mg, croscarmellose sodium 15 mg, silicone dioxide 5 mg, starch 20 mg, magnesium stearate 5 mg, talc 5 mg and purified water as needed.

L27 ANSWER 2 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:1124928 HCAPLUS

DOCUMENT NUMBER: 145:443952

TITLE: Compositions comprising aminergic compounds and complement compounds, such as ascorbates, cysteines, opioids, resveratrols, and polycarboxylic acid chelators

INVENTOR(S): Dillon, Patrick F.; Root-Bernstein, Robert S.

PATENT ASSIGNEE(S): Board of Trustees of Michigan State University, USA

SOURCE: PCT Int. Appl., 71pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006113485	A2	20061026	WO 2006-US14165	20060414
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.:
 US 2005-672224P P 20050415
 US 2005-706249P P 20050805
 US 2005-738294P P 20051118

AB Pharmaceutical compns. and method using aminergic compds. and complement compds. are provided comprising: (a) a subefficacious amount of a non-adrenergic aminergic compound or of an adrenergic antagonist; and (b) a safe and effective amount of a complement compound. Methods are also provided comprising the administration of: (a) a low dose of a non-adrenergic aminergic compound or any adrenergic antagonist; and (b) a safe and effective amount of a complement compound. Non-adrenergic aminergic compds. can comprise a histaminergic, dopaminergic, muscarinergic, serotonergic, octopaminergic, or trace aminergic compound. Complement compds. include ascorbates, opioids, polycarboxylic acid chelators, resveratrols, cysteines, substituted derivs. and analogs thereof, and mixts. thereof. Preferred complements include ascorbates, particularly ascorbic acid. Methods include the treatment of neurol. and neural disorders; mood and behavior disorders; cardiac, vascular, and cardiovascular disorders; hypertension, headache; respiratory disorders; gastrointestinal disorders; obesity; asthma, allergy; smooth muscle contraction disorders; nasal or nasopharyngeal conditions; genitourinary disorders; ocular disorders, glaucoma; and hormone- or neurotransmitter-release or -secretion disorders.

L27 ANSWER 3 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:768914 HCAPLUS

DOCUMENT NUMBER: 145:195718

TITLE: Analgesic controlled release compositions for treatment of pain-related sleep disturbance

INVENTOR(S): Staniforth, John

PATENT ASSIGNEE(S): Pharmakodex Ltd., UK

SOURCE: PCT Int. Appl., 28pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006079853	A1	20060803	WO 2006-GB50025	20060130
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: GB 2005-1809 A 20050128

AB The present invention relates to oral pharmaceutical compns. comprising an analgesic agent and providing controlled release of the agent for improved treatment and prevention of pain and pain-related conditions, such as pain-related sleep disturbance. The invention is particularly concerned with self-administered compns. The composition comprises two or more analgesic agents, i.e., a combination of an antimigraine agent and a nonsteroidal anti-inflammatory drug, or a tricyclic antidepressant and a GABA agonist. For example, a composition comprised a combination of amitriptyline and gabapentin.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 4 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:317459 HCAPLUS

DOCUMENT NUMBER: 144:357702
 TITLE: Solid unit dosage forms of 5-HT1 agonists
 INVENTOR(S): Nimbalkar, Sudarshan; Deo, Kishor Dattatray; Aga, Hidaytulla Shamshuddin; Meenakshisunderam, Sivakumaran
 PATENT ASSIGNEE(S): Aurobindo Pharma Ltd., India
 SOURCE: PCT Int. Appl., 15 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006035313	A1	20060406	WO 2005-IB3100	20050926
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

IN 2004CH00998 A 20070622 IN 2004-CH998 20040929
 EP 1793808 A1 20070613 EP 2005-800124 20050926
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR

PRIORITY APPLN. INFO.: IN 2004-CH998 A 20040929
 WO 2005-IB3100 W 20050926

AB The present invention relates to pharmaceutical compns. of 5-HT1 agonist. More particularly, the present invention relates to uncoated tablets of sumatriptan succinate. The present invention also relates to a process for the preparation of uncoated tablets of sumatriptan succinate. Tablets of sumatriptan contained Dicalcium phosphate 140.00 mg.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 5 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:268948 HCAPLUS
 DOCUMENT NUMBER: 144:331434
 TITLE: Preparation of tricyclic anilide spirohydantoin CGRP receptor antagonists
 INVENTOR(S): Bell, Ian M.; Gallicchio, Steven N.; Zartman, C. Blair; Theberge, Cory R.; Zhang, Xufang
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA
 SOURCE: PCT Int. Appl., 84 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006031676	A2	20060323	WO 2005-US32288	20050909
WO 2006031676	A3	20070426		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,				

LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

AU 2005285083 A1 20060323 AU 2005-285083 20050909
CA 2579850 A1 20060323 CA 2005-2579850 20050909
EP 1794146 A2 20070613 EP 2005-796599 20050909

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
BA, HR, MK, YU

IN 2007DN01494 A 20070803 IN 2007-DN1494 20070223
PRIORITY APPLN. INFO.: US 2004-609294P P 20040913
WO 2005-US32288 W 20050909

OTHER SOURCE(S): MARPAT 144:331434

AB Title compds. I [A1 and A2 independently = bond or CR13R14, where one of A1 and A2 is optionally absent; B1 and B4 independently = C when double bond present, CR1 or N; B2 and B3 independently = bond, CR1R2, CO, CS, O, S, etc., where one of B2 and B3 is optionally absent; D1 and D2 independently = O, S, SO2, CR1R2, CO, etc.; T, U and V independently = =C(R1)- and =N-, wherein at least one of T, U, and V = =C(R1)-; W, X, Y, and Z = bond, CR1R2, CS, O, etc.; R1 and R2 = H, (un)substituted alkyl, cycloalkyl, alkynyl, etc.; R4 = H, (un)substituted alkyl, benzyl, etc.; R5a, R5b, and R5c = H, alkyl, alkoxy, halo, etc.; R6 = H, (un)substituted alkyl, cycloalkyl, etc.; R13 and R14 = H, OH, halo, and (un)substituted alkyl; m = 1 or 2; n = 1 or 2], and their pharmaceutically acceptable salts, useful as antagonists of calcitonin gene-related peptide (CGRP) receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. Thus, e.g., II was prepared by reaction of (-)-5'-amino-3-methylspiro[imidazolidine-4,2'-indane]-2,5-dione (preparation given) with sodium (2,5-dioxo-5,6-dihydro-4H-imidazo[1,5,4-de]quinoxalin-1(2H)yl)acetate (preparation given). I demonstrated activity as antagonists of the CGRP receptor with Ki or IC50 values generally less than about 50 µM. The invention is also directed to pharmaceutical compns. comprising these compds. and the use of these compds. and compns. in the prevention or treatment of such diseases in which CGRP is involved.

L27 ANSWER 6 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:269508 HCAPLUS

DOCUMENT NUMBER: 144:331420

TITLE: Preparation of bicyclic anilide spirolactam cgrp receptor antagonists

INVENTOR(S): Bell, Ian M.; Theberge, Cory R.; Stump, Craig A.; Zhang, Xufang; Gallicchio, Steven N.; Zartman, C. Blair

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 116 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006031610	A2	20060323	WO 2005-US32041	20050909
WO 2006031610	A3	20060831		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,			

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
 LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
 NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
 SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
 ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM

AU 2005285109 A1 20060323 AU 2005-285109 20050909

CA 2579847 A1 20060323 CA 2005-2579847 20050909

EP 1797073 A2 20070620 EP 2005-795448 20050909

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR

CN 101018781 A 20070815 CN 2005-80030605 20050909

IN 2007DN01493 A 20070803 IN 2007-DN1493 20070223

PRIORITY APPLN. INFO.: US 2004-609292P P 20040913

WO 2005-US32041 W 20050909

OTHER SOURCE(S): MARPAT 144:331420

AB Title compds. I [A1 and A2 independently = bond or CR13R14, where one of
 A1 and A2 is optionally absent; B = (un)substituted bicycloheterocycle; J
 = =C(R6a)-; CR13R14, and CO; K = =C(R6b), CR13R14, CO, etc.; R4 = H,
 (un)substituted alkyl, benzyl, etc.; R5a, R5b, and R5c = H, alkyl, alkoxy,
 halo, etc.; R6a and R6b independently = H, OH, halo, (un)substituted
 alkyl, etc.; R13 and R14 = H or (un)substituted alkyl; m = 1 or 2; n = 1
 or 2], and their pharmaceutically acceptable salts, useful as antagonists
 of calcitonin gene-related peptide (CGRP) receptors and useful in the
 treatment or prevention of diseases in which the CGRP is involved, such as
 headache, migraine and cluster headache. Thus, e.g., II was
 prepared by reaction of 5-amino-1,3-dihydro-2'H,5'H-spiro[indene-2,3'-
 pyrrolidine]-2',5'-dione (preparation given) with 5-amino-1,3-
 dihydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one (preparation
 given). I demonstrated activity as antagonists of the CGRP receptor with
 Ki or IC50 values generally less than about 50 µM. The invention is
 also directed to pharmaceutical compns. comprising these compds.
 and the use of these compds. and compns. in the prevention or treatment of
 such diseases in which CGRP is involved.

L27 ANSWER 7 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:269581 HCAPLUS

DOCUMENT NUMBER: 144:312071

TITLE: Preparation of tricyclic anilide spiro lactam CGRP
 receptor antagonists

INVENTOR(S): Bell, Ian M.; Gallicchio, Steven N.; Stump, Craig A.;
 Theberge, Cory R.; Vacca, Joseph P.; Zartman, C.
 Blair; Zhang, Xufang

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 121 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006031491	A2	20060323	WO 2005-US31617	20050906
WO 2006031491	A3	20061109		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
 LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
 NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,

SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
 ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM

AU 2005285270	A1	20060323	AU 2005-285270	20050906
CA 2579717	A1	20060323	CA 2005-2579717	20050906
EP 1793827	A2	20070613	EP 2005-796847	20050906
CN 101014345	A	20070808	CN 2005-80029991	20050906
IN 2007DN01195	A	20070803	IN 2007-DN1195	20070213
PRIORITY APPLN. INFO.:			US 2004-608294P	P 20040909
			WO 2005-US31617	W 20050906

OTHER SOURCE(S): MARPAT 144:312071

AB Title compds. I [A1 and A2 independently = bond or CR13R14, where one of A1 and A2 is optionally absent; B1 and B4 independently = C when double bond present, CR1 or N; B2 and B3 independently = bond, CR1R2, CO, CS, O, S, etc., where one of B2 and B3 is optionally absent; D1 and D2 independently = O, S, SO2, CR1R2, CO, etc.; J = =C(R6a)-; CR13R14, and CO; K = =C(R6b), CR13R14, CO, etc.; T, U and V independently = =C(R1)- and =N-, wherein at least one of T, U, and V = =C(R1)-; W, X, Y, and Z = bond, CR1R2, CS, O, etc.; R1 and R2 = H, (un)substituted alkyl, cycloalkyl, alkynyl, etc.; R4 = H, (un)substituted alkyl, benzyl, etc.; R5a, R5b, and R5c = H, alkyl, alkoxy, halo, etc.; R6a = H, OH, halo, CN, (un)substituted alkyl, etc.; R13 and R14 = H, OH, halo, and (un)substituted alkyl; m = 1 or 2; n = 1 or 2], and their pharmaceutically acceptable salts, useful as antagonists of calcitonin gene-related peptide (CGRP) receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. Thus, e.g., II was prepared by reaction of (-)-5-amino-1,3-dihydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-2'-(1'H)-one (preparation given) with lithium (4-oxo-2a,3,4,5-tetrahydropyrrolo[4,3,2-de]quinolin-1(2H)-yl)acetate (preparation given). I demonstrated activity as antagonists of the CGRP receptor with Ki or IC50 values generally less than about 50 µM. The invention is also directed to pharmaceutical compns. comprising these compds. and the use of these compds. and compns. in the prevention or treatment of such diseases in which CGRP is involved.

L27 ANSWER 8 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:636805 HCAPLUS
 DOCUMENT NUMBER: 145:96481
 TITLE: Use of selected CGRP antagonists in combination with other antimigraine drugs for the treatment of migraine
 INVENTOR(S): Rudolf, Klaus; Doods, Henri; Mueller, Stephan Georg; Zamponi, Annette; Lustenberger, Philipp; Arndt, Kirsten; Schaenzle, Gerhard; Stenkamp, Dirk; Brickl, Rolf-Stefan
 PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany
 SOURCE: U.S. Pat. Appl. Publ., 22 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006142273	A1	20060629	US 2005-275169	20051216
DE 102004063753	A1	20060713	DE 2004-102004063753	20041229
WO 2006072413	A1	20060713	WO 2005-EP13964	20051223
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
 KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
 MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
 SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
 VN, YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: DE 2004-102004063753A 20041229

AB The invention discloses a process for the treatment or prevention of indications which are selected from among the group comprising headaches, migraine and cluster headaches, the process comprising the joint administration of a therapeutically effective amount of a selected CGRP antagonist (A), a physiol. acceptable salt thereof or a hydrate of the salt and a therapeutically effective amount of a second or third active anti-migraine medicament (B), particularly sumatriptan, zolmitriptan, or dihydroergotamine, or a physiol. acceptable salt thereof, as well as the corresponding pharmaceutical compns. and the preparation thereof. A variety of formulations are included.

L27 ANSWER 9 OF 39 SCISEARCH COPYRIGHT (c) 2007 The Thomson Corporation on STN

ACCESSION NUMBER: 2006:57803 SCISEARCH

THE GENUINE ARTICLE: 000CA

TITLE: Safety and efficacy of eletriptan in the treatment of acute migraine

AUTHOR: Takiya L (Reprint); Piccininni L C; Kamath V

CORPORATE SOURCE: Univ Sci Philadelphia, Dept Pharm Practice & Pharm Adm, Philadelphia Coll Pharm, 600 S 43rd St, Philadelphia, PA 19104 USA (Reprint); Univ Sci Philadelphia, Dept Pharm Practice & Pharm Adm, Philadelphia Coll Pharm, Philadelphia, PA 19104 USA; Vet Adm, Dept Pharm, New Jersey Healthcare Syst, E Orange, NJ USA; Union Mem Hosp, Dept Pharm, Baltimore, MD USA
 l.takiya@usip.edu

COUNTRY OF AUTHOR: USA

SOURCE: PHARMACOTHERAPY, (JAN 2006) Vol. 26, No. 1, pp. 115-128.
 ISSN: 0277-0008.

PUBLISHER: PHARMACOTHERAPY PUBLICATIONS INC, NEW ENGLAND MEDICAL CENTER, 806, 750 WASHINGTON ST, BOSTON, MA 02111 USA.

DOCUMENT TYPE: Article; Journal

LANGUAGE: English

REFERENCE COUNT: 46

ENTRY DATE: Entered STN: 19 Jan 2006

Last Updated on STN: 19 Jan 2006

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB Eletriptan is a new selective serotonin agonist approved for the treatment of acute migraine headaches. To review the pharmacologic, pharmacodynamic, pharmacokinetic, safety, and clinical efficacy data for eletriptan, we searched the literature in PubMed/MEDLINE, EMBASE, International Pharmaceutical Abstracts, and Science Direct databases to gather all published reports from January 1996-October 2004. All English-language reports (abstract or full trial reports) about the pharmacology, pharmacokinetics, clinical efficacy, and safety of eletriptan were reviewed. Eletriptan's pharmacokinetic and pharmacodynamic parameters translate into a favorable safety and efficacy profile. The drug is rapidly absorbed when administered orally, has good bioavailability and central nervous system penetration due to its lipophilicity, and has a long half-life, which contributes to its ability to prevent recurrent headaches. Compared with other serotonin agonists, eletriptan has a longer duration of action and greater lipophilicity. Eletriptan is metabolized through the cytochrome P450 3A4 system;

therefore, it does have the potential for clinically significant drug interactions. In clinical trials, eletriptan demonstrated efficacy superior to that of placebo and similar or superior efficacy to that of other serotonin agonists, with limited adverse effects. With clinical use, headache and pain-free responses and headache recurrence rates were similar to those of other serotonin agonists, but the agent is superior to ergotamine tartrate-caffeine. Based on pharmacoeconomic data, eletriptan is more cost-effective than other agents in its class. Eletriptan is a safe and cost-effective option for the treatment of migraine headaches.

L27 ANSWER 10 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:177844 HCAPLUS
 DOCUMENT NUMBER: 142:266766
 TITLE: Pharmaceuticals for delivering 5-HT agonists across the oral mucosa
 INVENTOR(S): Singh, Nikhilesh N.
 PATENT ASSIGNEE(S): Transoral Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 77 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005018565	A2	20050303	WO 2004-US27156	20040818
WO 2005018565	A3	20050602		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004266731	A1	20050303	AU 2004-266731	20040818
CA 2535803	A1	20050303	CA 2004-2535803	20040818
EP 1656102	A2	20060517	EP 2004-781773	20040818
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
CN 1842317	A	20061004	CN 2004-80023867	20040818
JP 2007502839	T	20070215	JP 2006-524083	20040818
IN 2006KN00615	A	20070803	IN 2006-KN615	20060316
US 2007059254	A1	20070315	US 2006-567658	20061027
PRIORITY APPLN. INFO.:			US 2003-560748P	P 20030821
			US 2004-598672P	P 20040803
			WO 2004-US27156	W 20040818

AB The present invention provides novel compns. for the delivery of a 5-hydroxytryptamine (5-HT) agonist across the oral mucosa. In particular, the buffer system in the compns. of the present invention raises the pH of saliva to a pH >9.9, thereby facilitating the substantially complete conversion of the 5-HT agonist from its ionized to its unionized form. As a result, the dose of 5-HT agonist is rapidly and efficiently absorbed by the oral mucosa. Furthermore, delivery of the 5-HT agonist across the oral mucosa advantageously bypasses hepatic first pass metabolism of the drug and avoids enzymic degradation of the drug within the gastrointestinal tract. Methods for using the compns. of the present invention for treating

migraines are also provided. Thus, a lozenge formulation contained Na₂CO₃ 14.000, NaHCO₃ 23.000, sumatriptan 9.000. Mannogem EZ 40.000, Sorbogem-712 80.000, MgO 63.400, flavor 6.500, Sucralose 1.100, SiO₂ 5.500, and Mg stearate 7.500 mg.

L27 ANSWER 11 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:14369 HCAPLUS
DOCUMENT NUMBER: 142:114110
TITLE: Preparation of benzodiazepine CGRP receptor antagonists
INVENTOR(S): Burgey, Christopher S.; Stump, Craig A.; Williams, Theresa M.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005000807	A2	20050106	WO 2004-US20206	20040624
WO 2005000807	A3	20060105		
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	
RW:			BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
AU 2004252150	A1	20050106	AU 2004-252150	20040624
CA 2529227	A1	20050106	CA 2004-2529227	20040624
EP 1641781	A2	20060405	EP 2004-776996	20040624
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR	
CN 1812982	A	20060802	CN 2004-80017952	20040624
JP 2007516182	T	20070621	JP 2006-517597	20040624
US 2006148790	A1	20060706	US 2005-562298	20051222
US 7196079	B2	20070327		
PRIORITY APPLN. INFO.:			US 2003-482674P	P 20030626
			WO 2004-US20206	W 20040624

OTHER SOURCE(S): CASREACT 142:114110; MARPAT 142:114110

AB Title compds. I [R₁ = H, alk(en/yn)yl, etc.; R₂ = H, alkyl, cycloalkyl, etc.; R₇ = H, alk(en/yn)yl, etc.; W = O, amino, alkyl; X = C, S; Y = O, NCN, etc.; R₃ = H, alkyl, CN, etc.; R₆ = H, alkyl, cycloalkyl, etc.; G-J = N, N-alkyl, etc.] are prepared For instance, II is prepared from (R)-3-amino-1-ethyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine oxalate, p-nitrophenylchloroformate and 3-(piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one hydrochloride. Compds. I exhibit affinity for the CGRP receptor with an IC₅₀ of less than 50µM. I, alone or in combination with other agents, are useful for the treatment of diseases in which the CGRP is involved, such as headache, migraine and cluster headache.

L27 ANSWER 12 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:409237 HCAPLUS
DOCUMENT NUMBER: 142:441892
TITLE: Migraine treatments including isovaleramide compounds and serotonin agonists

INVENTOR(S): Artman, Linda D.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 12 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005101655	A1	20050512	US 2004-987760	20041112
CA 2545771	A1	20050526	CA 2004-2545771	20041112
WO 2005046659	A2	20050526	WO 2004-US37783	20041112
WO 2005046659	A3	20060803		
WO 2005046659	A8	20060928		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1682104	A2	20060726	EP 2004-801018	20041112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				

PRIORITY APPLN. INFO.: US 2003-519243P P 20031112
 WO 2004-US37783 W 20041112

AB A method is disclosed of treating a migraine headache comprising administration of at least one serotonin agonist and isovaleramide, α -Me isovaleramide, or mixts. thereof to a patient suffering from a migraine. Method involves at least one serotonin agonist that is selected from the group consisting of sumatriptan, elepatriptan, naratriptan, rizatriptan, zolmitriptan, almotriptan, frovatriptan, ergotamine, an ergotamine derivative, and mixts. thereof.

L27 ANSWER 13 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:1156454 HCAPLUS
 DOCUMENT NUMBER: 142:69205
 TITLE: Topical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
 INVENTOR(S): Aung-Din, Ronald
 PATENT ASSIGNEE(S): USA
 SOURCE: PCT Int. Appl., 50 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004112723	A2	20041229	WO 2004-US19816	20040621
WO 2004112723	A3	20050728		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

CA 2529528 A1 20041229 CA 2004-2529528 20040621
 EP 1644004 A2 20060412 EP 2004-755770 20040621
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
 US 2007065463 A1 20070322 US 2006-560889 20060515
 PRIORITY APPLN. INFO.: US 2003-480088P P 20030620
 US 2003-480089P P 20030620
 US 2003-513082P P 20031021
 WO 2004-US19816 W 20040621

AB The invention is directed to topical formulations and methods of treating
 a migraines and/or cluster headaches, muscle sprains, muscle
 spasms, spasticity, tension headaches, tension related migraines
 and related conditions associated with muscle tension and pain with a
 therapeutically effective amount of an ergot alkaloid, skeletal muscle
 relaxant, serotonin agonist, combinations thereof, pharmaceutically
 acceptable salt thereof, prodrugs thereof or derivative thereof.

L27 ANSWER 14 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:681407 HCAPLUS
 DOCUMENT NUMBER: 141:195316
 TITLE: Rapid absorption selective 5-HT
 agonist formulations
 INVENTOR(S): Mezaache, Naima; Mezaache, Djelila; Frisbee, Steve;
 Maes, Paul
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 45 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004162333	A1	20040819	US 2004-779784	20040218
AU 2004212976	A1	20040902	AU 2004-212976	20040218
CA 2514875	A1	20040902	CA 2004-2514875	20040218
WO 2004073632	A2	20040902	WO 2004-US4572	20040218
WO 2004073632	A3	20041118		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
 BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
 MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
 GQ, GW, ML, MR, NE, SN, TD, TG

EP 1594470 A2 20051116 EP 2004-712297 20040218
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2006523620 T 20061019 JP 2006-503623 20040218
 MX 2005PA08838 A 20060217 MX 2005-PA8838 20050819
 NO 2005004015 A 20050916 NO 2005-4015 20050830

PRIORITY APPLN. INFO.: US 2003-447741P P 20030219
 WO 2004-US4572 W 20040218

AB The invention provides for a rapid absorption pharmaceutical
 composition comprising an effective amount of at least one selective 5-

HT agonist, at least one spheronization aid and at least one solubility enhancer. The composition of the invention is incorporated into microparticles, which may be subsequently taste-masked and incorporated into a variety of dosage forms for administration to a patient suffering from migraine. Uncoated microparticles contained sumatriptan succinate 30, glyceryl palmitostearate 65, and Macrogol fatty acid esters (Gelucire 50/13) 5%.

L27 ANSWER 15 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:897601 HCAPLUS
DOCUMENT NUMBER: 142:189886
TITLE: Treatment of migraine headaches with sumatriptan in pregnancy
AUTHOR(S): Hilaire, Michelle L.; Cross, L. Brian; Eichner, Samantha F.
CORPORATE SOURCE: University of Tennessee Family Practice Center, Memphis, TN, USA
SOURCE: Annals of Pharmacotherapy (2004), 38(10), 1726-1730
CODEN: APHRER; ISSN: 1060-0280
PUBLISHER: Harvey Whitney Books Co.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review on treatment of migraine headaches with sumatriptan during pregnancy. Studies and reports were located in International Pharmaceutical Abstrs. (1970-Sept. 2003) and MEDLINE (1966-wk 3 Sept. 2003). Research has been performed to evaluate the risk of teratogenesis after sumatriptan exposure in pregnant patients. Data have been collected in areas including placental transmission of sumatriptan, prospective pregnancy registries, open-labeled and controlled prospective studies, and a retrospective prescription-linked study. As of August 6, 2004, no randomized controlled trials have been conducted with exposure to sumatriptan during pregnancy. Teratogenesis occurs in approx. 150 000 births per yr which represents an incidence of 3-5%. Available literature to date indicates that exposure to sumatriptan during pregnancy has no addnl. risk of birth defects compared with the incidence in the general population.

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 16 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:649142 HCAPLUS
DOCUMENT NUMBER: 142:69122
TITLE: Efficacy of 1,000 mg Effervescent Acetylsalicylic Acid and Sumatriptan in Treating Associated Migraine Symptoms
AUTHOR(S): Diener, H. C.; Eikermann, A.; Gessner, U.; Goebel, H.; Haag, G.; Lange, R.; May, A.; Mueller-Schwefe, G.; Voelker, M.
CORPORATE SOURCE: Department of Neurology, University of Essen, Essen, Germany
SOURCE: European Neurology (2004), 52(1), 50-56
CODEN: EUNEAP; ISSN: 0014-3022
PUBLISHER: S. Karger AG
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Recently a new effervescent acetylsalicylic acid (ASA) tablet with high buffering capacity has been developed. In this double-blind, 3-arm, multicenter, parallel-group study, 433 patients were treated either with 1,000 mg effervescent ASA or 50 mg encapsulated sumatriptan or placebo. The primary endpoint was the percentage of patients with complete remission of the 3 accompanying symptoms nausea, photophobia and phonophobia within 2 h after intake of the study drug. 43.8% Of patients treated with ASA, 43.7% of patients treated with sumatriptan and 30.9% of patients treated with placebo showed complete remission of all 3

accompanying symptoms ($p < 0.05$ for ASA and sumatriptan vs. placebo). Both active treatments were superior to placebo regarding the individual symptoms photophobia and phonophobia, but not for nausea. The percentage of patients with reduction in headache severity from moderate or severe to mild or no pain (secondary objective) was 49.3% for ASA, 48.8% for sumatriptan and 32.9% for placebo. All active treatments were superior to placebo ($p < 0.05$). 25.3, 24.4 and 14.5% of patients treated with ASA, sumatriptan or placebo were pain free at 2 h. Drug-related adverse events were reported in 3.9, 4.7 and 6.7% of patients treated with placebo, ASA or sumatriptan. The study showed that administration of effervescent ASA leads to remission of the migraine symptoms nausea, photophobia and phonophobia, reduces migraine headache and is comparable to sumatriptan.

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 17 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:454096 HCAPLUS

DOCUMENT NUMBER: 139:12333

TITLE: Pharmaceutical compositions containing a 5HT-1 receptor agonist

INVENTOR(S): Baker, Robert William; Dow, Alan David; Summers, Simon John; Westrup, Julian

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003047552	A2	20030612	WO 2002-EP13715	20021204
WO 2003047552	A3	20030925		
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
FI 2002002128	A	20030606	FI 2002-2128	20021203
NO 2002005805	A	20030606	NO 2002-5805	20021203
TW 240638	B	20051001	TW 2002-91134979	20021203
CA 2469019	C	20030612	CA 2002-2469019	20021204
CA 2469019	A1	20030612		
AU 2002358602	A1	20030617	AU 2002-358602	20021204
EP 1450770	A2	20040901	EP 2002-792887	20021204
EP 1450770	B1	20050330		
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK	
BR 2002014497	A	20041019	BR 2002-14497	20021204
HU 200402178	A2	20050228	HU 2004-2178	20021204
AT 291900	T	20050415	AT 2002-792887	20021204
CN 1610539	A	20050427	CN 2002-824418	20021204
EP 1527773	A1	20050504	EP 2005-75288	20021204
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, SK	
NZ 532829	A	20050527	NZ 2002-532829	20021204
JP 2005515991	T	20050602	JP 2003-548808	20021204

JP 3699969	B2	20050928		
ES 2236608	T3	20050716	ES 2002-2792887	20021204
IL 161997	A	20051218	IL 2002-161997	20021204
RU 2285526	C2	20061020	RU 2004-120292	20021204
IN 2004DN01294	A	20050401	IN 2004-DN1294	20040514
ZA 2004003849	A	20050829	ZA 2004-3849	20040519
MX 2004PA05420	A	20041011	MX 2004-PA5420	20040604
US 2005032867	A1	20050210	US 2004-497749	20040920
HK 1069111	A1	20051014	HK 2005-101699	20050228
PRIORITY APPLN. INFO.:			GB 2001-29117	A 20011205
			EP 2002-792887	A3 20021204
			WO 2002-EP13715	W 20021204

AB The present invention relates to a pharmaceutical composition for oral administration capable of rapid disintegration and dispersion within the gastrointestinal tract comprising a 5HT-1 receptor agonist as active ingredient (e.g., sumatriptan), in particular a composition in solid-dosage form that is intended to be swallowed, and methods of treatment of cephalic pain, especially migraine, using such composition. Thus, tablet contained sumatriptan succinate 140, dibasic calcium phosphate 140, microcryst. cellulose 3.5, croscarmellose sodium 15, NaHCO₃ 30, and Mg stearate 1.5 mg/tablet.

L27 ANSWER 18 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:153396 HCAPLUS

DOCUMENT NUMBER: 138:180766

TITLE: Use of BIBN4096BS in combination with other antimigraine medications for the treatment of headache, migraine or cluster headache

INVENTOR(S): Doods, Henri; Hurnaus, Rudolf; Eberlein, Wolfgang

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma KG, Germany

SOURCE: Ger. Offen., 14 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10139410	A1	20030227	DE 2001-10139410	20010817
CA 2454083	A1	20030227	CA 2002-2454083	20020810
WO 2003015787	A1	20030227	WO 2002-EP8993	20020810
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002333393	A1	20030303	AU 2002-333393	20020810
EP 1420790	A1	20040526	EP 2002-794772	20020810
EP 1420790	B1	20050921		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002011970	A	20040921	BR 2002-11970	20020810
CN 1543347	A	20041103	CN 2002-816132	20020810
HU 200401484	A2	20041228	HU 2004-1484	20020810
HU 200401484	A3	20070328		
JP 2005503382	T	20050203	JP 2003-520746	20020810
AT 304854	T	20051015	AT 2002-794772	20020810
ES 2250733	T3	20060416	ES 2002-2794772	20020810

US 2003181462	A1	20030925	US 2002-218136	20020813
ZA 2004000313	A	20041101	ZA 2004-313	20040115
IN 2004DN00213	A	20050401	IN 2004-DN213	20040129
MX 2004PA01364	A	20040527	MX 2004-PA1364	20040213
US 2006183693	A1	20060817	US 2006-276603	20060307
PRIORITY APPLN. INFO.:			DE 2001-10139410	A 20010817
			US 2001-315321P	P 20010828
			US 2002-215612	B2 20020809
			WO 2002-EP8993	W 20020810
			US 2002-218136	B1 20020813

AB The invention provides a method for the treatment or prevention of headache, migraine, or cluster headache, which involves the common administration of a therapeutically effective amount of 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]-carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine [BIBN4096BS], or a physiol. acceptable salt thereof, and a therapeutically effective amount of a second active antimigraine medication, in particular sumatriptan, zolmitriptan, or dihydroergotamine, or a physiol. acceptable salt thereof. Pharmaceutical compns. and production thereof are also provided.

L27 ANSWER 19 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:964146 HCAPLUS

DOCUMENT NUMBER: 138:39187

TITLE: Preparation of piperidinecarboxylates and related compounds as NMDA NR2B receptor antagonists for the treatment or prevention of migraine.

INVENTOR(S): Allen, Christopher; Koblan, Ken S.; Sleeth, Timothy

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 185 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2002100352	A2	20021219	WO 2002-US21069	20020607
WO 2002100352	A3	20030327		
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
CA 2449249	A1	20021219	CA 2002-2449249	20020607
AU 2002346050	A1	20021223	AU 2002-346050	20020607
EP 1399160	A2	20040324	EP 2002-744807	20020607
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR	
JP 2004537526	T	20041216	JP 2003-503178	20020607
US 2004204341	A1	20041014	US 2003-479923	20031205
PRIORITY APPLN. INFO.:			US 2001-297672P	P 20010612
			WO 2002-US21069	W 20020607

AB A method for treating or preventing migraines comprises administration of an NR2B receptor antagonist (no data). The invention also encompasses the combination of an NR2B antagonist with a cyclooxygenase-2 selective inhibitor, a calcitonin gene-related peptide receptor (CGRP) ligand, a leukotriene receptor antagonist, or a 5HT1B/1D

agonist for the treatment or prevention of migraines. Thus, 4-hydroxybenzoic acid, 1-hydroxybenzotriazole hydrate, benzyl 4-(aminomethyl)piperidine-1-carboxylate (preparation given), and Et3N in DMF were treated with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and the mixture allowed to stir at room temperature for 18 h to give 4-[(4-hydroxybenzoylamino)methyl]piperidine-1-carboxylic acid benzyl ester.

L27 ANSWER 20 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:479056 HCAPLUS
DOCUMENT NUMBER: 138:32651
TITLE: Recent advances in 5-HT1B/1D receptor antagonists and agonists and their potential therapeutic applications
AUTHOR(S): Slassi, Abdelmalik
CORPORATE SOURCE: Medicinal Chemistry Department, NPS Pharmaceuticals, Mississauga, ON, L4V 1V7, Can.
SOURCE: Current Topics in Medicinal Chemistry (Hilversum, Netherlands) (2002), 2(6), 559-574
CODEN: CTMCCL; ISSN: 1568-0266
PUBLISHER: Bentham Science Publishers Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. The human 5-HT1B and 5-HT1D receptors are especially similar in sequence despite being encoded by two distinct genes. Although, human 5-HT1B and 5-HT1D receptors have been pharmacol. differentiated using nonselective 5-HT1B/D receptor antagonists such as ketanserin (1), ritanserin (2) and methiothepin (3), the precise function of these receptors remains undefined, and progress toward this has been hampered by the lack of selective ligands. The interest of the major pharmaceutical companies in 5-HT1B/1D antagonists increased by the discovery of potent and selective tools, combined with the fact that the blockade of terminal 5-HT1B receptors by selective antagonists has been proposed as a new approach for more efficient and/or fast-acting antidepressant drugs, since the acute blockade of these 5-HT autoreceptors will, in theory, immediately mimic their desensitization. Furthermore, it has been also suggested that supersensitive 5-HT1B/1D receptors may be involved in the pathophysiol. of obsessive compulsive disorders (OCD). In the 5-HT1B/1D agonist field, since the discovery of sumatriptan (26) (a 5-HT1B/1D receptor agonist) as an effective treatment for migraine headache, intensive research in this area has led to several second-generation compds., a few of which have either entered the market place or are in late clin. trials. Beside the antimigraine activity of the 5-HT1B/1D agonists in clin. evaluation or already on the market, other potential therapeutic evaluations (such as gastric motor effect, bipolar disorder, autism, anti-aggressive effects) with these drugs are being investigated. This article highlights and reviews the research advances published in the 5-HT1B/1D antagonist and agonist literature. The article is supplemented with selected refs. on the design, synthesis and development of novel 5-HT1B/1D agents, and on studies to understand their mechanism and pathophysiol. Emphasis is given to recent advances in the potential therapeutic applications of 5-HT1B/1D serotonergic agents. By no means has any attempt been made to exhaustively review the literature but rather, primary refs. along with citations to recent literature reviews have been included in each section.

REFERENCE COUNT: 85 THERE ARE 85 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 21 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:452849 HCAPLUS
DOCUMENT NUMBER: 135:56081
TITLE: Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation resulting in acute migraine and other painful episodes associated

with neurovascular disorders
INVENTOR(S): Levin, Bruce H.
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 119 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001043733	A2	20010621	WO 2000-US33916	20001215
WO 2001043733	A3	20020510		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 1999-170817P P 19991215

AB Methods, kits, apparatus, and compns. for inhibiting cephalic inflammation, including meningeal inflammation and cerebral inflammation for example, in a human patient are provided. The treatment is for acute cerebral neurovascular disorders resulting in acute migraine and other painful episodes. The methods comprise intranasally administering to the patient a pharmaceutical composition comprising a local anesthetic, and preferably a long-acting local anesthetic ingredient. A composition useful for practicing the methods of the invention is described which comprises at least one local anesthetic in a pharmaceutically acceptable carrier, wherein the composition is formulated for intranasal delivery. A kit comprising the composition and an intranasal applicator is also included in the invention. Apparatus for delivering or applying the compns. of the invention or for performing the methods of the invention are also described.

L27 ANSWER 22 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:453494 HCAPLUS

DOCUMENT NUMBER: 135:41024

TITLE: Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation by intranasal administration of long-acting local anesthetic

INVENTOR(S): Levin, Bruce H.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 48 pp., Cont.-in-part of U.S. Ser. No. 118,615.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001004644	A1	20010621	US 2000-737302	20001215
US 2001055607	A1	20011227	US 1998-118615	19980717
US 6432986	B2	20020813		
US 2002010194	A1	20020124	US 2001-775724	20010201
US 2003133877	A1	20030717	US 2002-218138	20020812
US 2005281751	A1	20051222	US 2005-126475	20050511

PRIORITY APPLN. INFO.: US 1997-90110P P 19970721
US 1998-72845P P 19980128

US 1998-84559P	P 19980506
US 1998-118615	A2 19980717
US 1999-170817P	P 19991215
US 1997-897192	A 19970721
US 1999-117398P	P 19990127
US 2000-492946	A2 20000127
US 2000-737302	B2 20001215
US 2002-218138	A2 20020812

AB Methods, kits, apparatus, and compns. for inhibiting cephalic inflammation, including meningeal inflammation and cerebral inflammation for example, in a human patient are provided. The methods comprise intranasally administering to the patient a pharmaceutical composition comprising a local anesthetic, and preferably a long-acting local anesthetic ingredient. A composition useful for practicing the methods of the invention is described which comprises at least one local anesthetic in a pharmaceutically acceptable carrier, wherein the composition is formulated for intranasal delivery. A kit comprising the composition and an intranasal applicator is also included in the invention. Apparatus for delivering or applying the compns. of the invention or for performing the methods of the invention are also described. Ropivacaine was dorsonasally administered to individual patients experiencing head pain, other symptoms, or both, believed to be associated with an acute migraine episode. Dorsonasally administered ropivacaine rapidly inhibited of migraine in 92% of the ambulatory patients, as evidenced by an average 90% reduction in perceived pain within one hour, usually within 15 min or less. Symptoms of nausea and photophobia associated with acute migraine episodes in patients were similarly inhibited. Rebound of migraine occurred in only 5.4% of patients within twenty-four hours of treatment.

L27 ANSWER 23 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:10618 HCAPLUS

DOCUMENT NUMBER: 134:66162

TITLE: 5HT1 receptor agonists, caffeine and either a COX-2 inhibitor or NSAID for the treatment of migraine

INVENTOR(S): Sands, George Harry; Harrison, Wilma Marcia

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: Eur. Pat. Appl., 11 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1064967	A2	20010103	EP 2000-305369	20000626
EP 1064967	A3	20030205		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2312631	A1	20001230	CA 2000-2312631	20000628
ZA 2000003234	A	20020108	ZA 2000-3234	20000628
HU 200002507	A2	20010828	HU 2000-2507	20000629
JP 2001064180	A	20010313	JP 2000-197653	20000630

PRIORITY APPLN. INFO.: US 1999-141687P P 19990630

OTHER SOURCE(S): MARPAT 134:66162

AB The present invention relates to a method of treating migraine in a mammal, including a human, by administering to the mammal a 5HT1 receptor agonist, e.g. eletriptan, rizatriptan, zolmitriptan, sumatriptan, and naratriptan, and caffeine in combination with either a cyclooxygenase-2 (COX-2) inhibitor or a nonsteroidal antiinflammatory drug (NSAID). It also relates to pharmaceutical compns. containing a pharmaceutically acceptable carrier, a 5HT1 receptor

agonist and caffeine with either a COX-2 inhibitor or a NSAID,.

L27 ANSWER 24 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:10617 HCAPLUS

DOCUMENT NUMBER: 134:80829

TITLE: Combination of an 5HT1 receptor agonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine

INVENTOR(S): Harrison, Wilma Marcia; Sands, George Harry

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: Eur. Pat. Appl., 84 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1064966	A2	20010103	EP 2000-305312	20000623
EP 1064966	A3	20030108		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6476042	B1	20021105	US 2000-603630	20000626
ZA 2000003236	A	20020102	ZA 2000-3236	20000628
CA 2312989	A1	20001230	CA 2000-2312989	20000629
HU 200002509	A2	20010328	HU 2000-2509	20000629
JP 2001039870	A	20010213	JP 2000-197928	20000630
PRIORITY APPLN. INFO.:			US 1999-141715P	P 19990630

OTHER SOURCE(S): MARPAT 134:80829

AB The present invention relates to a method of treating migraine in a mammal, including a human, by administering to the mammal a 5HT1 receptor agonist, e.g. eletriptan, rizatriptan, zolmitriptan, sumatriptan, and naratriptan, in combination with caffeine and a cyclooxygenase-2 (COX-2) inhibitor, e.g. Vioxx, ethyl(2-benzoyl-6-chloro-1H-indol-3-yl)acetate, (2-benzoyl-6-chloro-1H-indol-3-yl)acetic acid, etc. It also relates to pharmaceutical compns. containing a pharmaceutically acceptable carrier, a 5HT1 receptor agonist with caffeine and a COX-2 inhibitor.

L27 ANSWER 25 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:862004 HCAPLUS

DOCUMENT NUMBER: 137:88277

TITLE: Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials

AUTHOR(S): Ferrari, Michel D.; Roon, Krista I.; Lipton, Richard B.; Goadsby, Peter J.

CORPORATE SOURCE: Department of Neurology, Leiden University Medical Centre, Leiden, 2300 RC, Neth.

SOURCE: Lancet (2001), 358(9294), 1668-1675

CODEN: LANCAO; ISSN: 0140-6736

PUBLISHER: Lancet Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Background The triptans, selective serotonin 5-HT1B/1D agonists, are very effective acute migraine drugs with a well-developed scientific rationale. Seven different triptans will soon be clin. available, making evidence-based selection guidelines necessary. Triptan trials have similar designs, facilitating meta-anal.; this will provide a foundation for using triptans in clin. practice. Method We asked pharmaceutical companies and the principal investigators of company-independent trials for raw patient data of all double-blind, randomized, controlled, clin. trials of oral triptans in migraine

We calculated summary ests. across studies for important efficacy and tolerability parameters, and sep. summarized direct comparator trials. Results 53 clin. trials (12 unpublished) involving 24089 patients, met the criteria for inclusion. Mean results for 100 mg sumatriptan were 59% (95% CI 57-60) for 2 h headache response (improvement from moderate or severe to mild or no pain); 29% (27-30) for 2 h pain free (improvement to no pain); 20% (18-21) for sustained pain free (pain free by 2 h and no headache recurrence or use of rescue medication 2-24 h post dose); and 67% (63-70) for consistency (response in at least two of three treated attacks); placebo-subtracted proportions for patients with at least one adverse event (AE) were 13% (8-18), for at least one central nervous system AE 6% (3-9), and for at least one chest AE 1.9% (1.0-2.7). Compared with these data, 10 mg rizatriptan showed better efficacy and consistency, and similar tolerability; 80 mg eletriptan showed better efficacy, similar consistency, but lower tolerability; 12.5 mg almotriptan showed similar efficacy at 2 h but better other results; 2.5 mg naratriptan and 20 mg eletriptan showed lower efficacy and (the first two) better tolerability; 2.5 mg and 5 mg zolmitriptan, 40 mg eletriptan, and 5 mg rizatriptan showed very similar results. The results of the 22 trials that directly compared triptans show the same overall pattern. We received no data on frovatriptan, but publicly available data suggest lower efficacy. Interpretation At marketed doses, all oral triptans were effective and well tolerated. 10 mg rizatriptan, 80 mg eletriptan, and 12.5 mg almotriptan provide the highest likelihood of consistent success.

REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 26 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:314539 HCAPLUS

DOCUMENT NUMBER: 132:329940

TITLE: Pharmaceutical compositions containing histaminergic agonist and COX-2 inhibitor for migraine treatment

INVENTOR(S): Simitchieva, Kremena; Reines, Scott A.; McKinney, Errol; Sandquist, Eric J.; Khanna, Deepak K.; Hargreaves, Richard

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 16 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000025779	A1	20000511	WO 1999-US25388	19991029
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2348979	A1	20000511	CA 1999-2348979	19991029
EP 1126841	A1	20010829	EP 1999-960171	19991029
EP 1126841	B1	20041215		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002528498	T	20020903	JP 2000-579220	19991029
AU 759307	B2	20030410	AU 2000-17098	19991029
AT 284691	T	20050115	AT 1999-960171	19991029

ES 2234324	T3	20050616	ES 1999-960171	19991029
US 2002016348	A1	20020207	US 2001-934823	20010822
US 6384034	B2	20020507		
US 2002177617	A1	20021128	US 2002-106845	20020326
US 2006194855	A1	20060831	US 2006-372694	20060310
PRIORITY APPLN. INFO.:			US 1998-106605P	P 19981102
			US 1999-429274	A1 19991029
			WO 1999-US25388	W 19991029
			US 2001-934823	A3 20010822
			US 2002-106845	A1 20020326

AB A combination of a 5HT1B/1D agonist and a cyclooxygenase-2 (COX-2) selective inhibitor is useful in the treatment and/or prevention of migraine. The 5HT1B/1D agonist is selected from sumatriptan, naratriptan, zolmitriptan, eletriptan, almotriptan, and rizatriptan, and the COX-2 inhibitor is selected from meloxicam, MK-663, Vioxx, RS 57067, celecoxib, and compound I. The 5HT1B/1D agonist and COX-2 inhibitor are administered combined in a single dosage form or as sep. dosage forms administered concurrently. Tablets containing 5 and 10 mg of rizatriptan benzoate and 10 mg Vioxx were prepared

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 27 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:314538 HCAPLUS

DOCUMENT NUMBER: 132:318049

TITLE: 5-HT1 receptor agonists and metoclopramide for the treatment of migraine

INVENTOR(S): Sands, George Harry

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 18 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000025778	A1	20000511	WO 1999-IB1694	19991018
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6255334	B1	20010703	US 1999-387990	19990901
CA 2348543	A1	20000511	CA 1999-2348543	19991018
AU 9959947	A	20000522	AU 1999-59947	19991018
BR 9914901	A	20010717	BR 1999-14901	19991018
EP 1126840	A1	20010829	EP 1999-971318	19991018
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200101174	T2	20011022	TR 2001-200101174	19991018
HU 200104696	A2	20020529	HU 2001-4696	19991018
JP 2002528497	T	20020903	JP 2000-579219	19991018
EE 200100243	A	20021216	EE 2001-243	19991018
TW 524692	B	20030321	TW 1999-88118594	19991027
IN 1999BO00728	A	20050304	IN 1999-BO728	19991027
US 2001020036	A1	20010906	US 2001-838440	20010419
NO 2001002013	A	20010424	NO 2001-2013	20010424
ZA 2001003322	A	20020610	ZA 2001-3322	20010424
HR 2001000298	A1	20020630	HR 2001-298	20010425

MX 2001PA04297	A	20000827	MX 2001-PA4297	20010427
BG 105534	A	20011231	BG 2001-105534	20010522
PRIORITY APPLN. INFO.:			US 1998-106328P	P 19981030
			US 1999-387990	A1 19990901
			WO 1999-IB1694	W 19991018

OTHER SOURCE(S): MARPAT 132:318049

AB A method for the treatment of migraine in a mammal, including a human, based on a pharmaceutical composition comprising a 5-HT₁ receptor agonist in combination with metoclopramide or administering the 5-HT₁ receptor orally and metoclopramide i.v. is described. The 5-HT₁ receptor agonist is selected from eletriptan, rizatriptan, sumatriptan, and naratriptan, but nor zolmitriptan. The 5-HT₁ receptor agonist is administered in an amount of 1-400 mg per day and metoclopramide is administered in an amount of 5-125 mg per kg per day. A method for enhancing pharmacokinetics of eletriptan for treatment of migraine comprises administration of eletriptan with metoclopramide.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 28 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:98329 HCAPLUS
DOCUMENT NUMBER: 132:141982
TITLE: Prevention of migraine recurrence
INVENTOR(S): Jackson, Neville Colin; Uden, Stephen
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000006161	A1	20000210	WO 1999-IB1105	19990614
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2338901	A1	20000210	CA 1999-2338901	19990614
AU 9939521	A	20000221	AU 1999-39521	19990614
BR 9912588	A	20010502	BR 1999-12588	19990614
EP 1100499	A1	20010523	EP 1999-922459	19990614
EP 1100499	B1	20040310		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
TR 200100314	T2	20010621	TR 2001-200100314	19990614
HU 200103424	A2	20020228	HU 2001-3424	19990614
EE 200100061	A	20020617	EE 2001-61	19990614
EE 4703	B1	20061016		
JP 2002521446	T	20020716	JP 2000-562016	19990614
JP 3824863	B2	20060920		
NZ 508736	A	20030926	NZ 1999-508736	19990614
AT 261304	T	20040315	AT 1999-922459	19990614
PT 1100499	T	20040630	PT 1999-922459	19990614
EP 1435237	A1	20040707	EP 2004-4644	19990614
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
CN 1522697	A	20040825	CN 2003-10102510	19990614

ES 2214027	T3	20040901	ES 1999-922459	19990614
EP 1466601	A2	20041013	EP 2004-4643	19990614
EP 1466601	A3	20050413		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
SG 125910	A1	20061030	SG 2003-200300769	19990614
TW 537893	B	20030621	TW 1999-88110233	19990617
TW 248362	B	20060201	TW 2003-92102563	19990617
NO 2001000489	A	20010326	NO 2001-489	20010129
MX 2001PA01097	A	20010629	MX 2001-PA1097	20010129
HR 2001000079	A1	20020228	HR 2001-79	20010130
BG 105277	A	20011130	BG 2001-105277	20010220
HK 1038198	A1	20041210	HK 2001-109100	20011227
AU 2003213493	A1	20030814	AU 2003-213493	20030716
AU 2003213495	A1	20030821	AU 2003-213495	20030716
NZ 527625	A	20050128	NZ 2003-527625	20030815
AU 2004222771	A1	20041111	AU 2004-222771	20041020

PRIORITY APPLN. INFO.:

GB 1998-16556	A	19980730
AU 1999-39521	A3	19990614
EP 1999-922459	A3	19990614
WO 1999-IB1105	W	19990614
AU 2003-213495	A3	20030716

AB The invention relates to the use of eletriptan, or a pharmaceutically acceptable salt or composition thereof, for the manufacture of a medicament for the prevention of migraine recurrence and to the use of a 5-HT1B/1D receptor agonist, or a pharmaceutically acceptable salt or composition thereof, for the manufacture of a dual-, sustained-, delayed-, controlled- or pulsed-release pharmaceutical composition for the prevention of migraine recurrence. A clin. example was given showing that eletriptan prevents migraine recurrence since when a second dose of eletriptan was administered following successful treatment of an initial migraine, the number of patients experiencing a migraine recurrence was at least halved compared with placebo.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 29 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:808507 HCAPLUS
DOCUMENT NUMBER: 133:329633
TITLE: 5-HT1 receptor agonist-COX-2 inhibitor combination for the treatment of migraine
INVENTOR(S): Sands, George Harry
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 12 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1051994	A2	20001115	EP 2000-303890	20000509
EP 1051994	A3	20030108		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2308824	A1	20001114	CA 2000-2308824	20000512
JP 2000336031	A	20001205	JP 2000-140270	20000512
HU 200001889	A2	20010528	HU 2000-1889	20000512
ZA 2000002343	A	20011112	ZA 2000-2343	20000512

PRIORITY APPLN. INFO.: US 1999-134309P P 19990514

OTHER SOURCE(S): MARPAT 133:329633

AB A method is provided for treating migraine in a mammal,

including a human, by administering a 5-HT1 receptor agonist in combination with a cyclooxygenase 2 (COX-2) inhibitor. Pharmaceutical compns. are also provided.

L27 ANSWER 30 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:808506 HCAPLUS
DOCUMENT NUMBER: 133:329632
TITLE: 5-HT1 receptor agonists and either a COX-2 inhibitor or NSAID for the treatment of migraine
INVENTOR(S): Sands, George Harry
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 11 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1051993	A2	20001115	EP 2000-303887	20000509
EP 1051993	A3	20030205		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AU 2000034009	A	20001116	AU 2000-34009	20000510
ZA 2000002311	A	20011112	ZA 2000-2311	20000511
CA 2308323	A1	20001114	CA 2000-2308323	20000512
HU 200001888	A2	20001228	HU 2000-1888	20000512
JP 2000344683	A	20001212	JP 2000-141445	20000515
PRIORITY APPLN. INFO.:			US 1999-134311P	P 19990514

OTHER SOURCE(S): MARPAT 133:329632

AB A method is provided for treating migraine in a mammal, including a human, by administering to the mammal a 5-HT1 receptor agonist in combination with either a cyclooxygenase-2 (COX-2) inhibitor or a nonsteroidal antiinflammatory drug (NSAID). Pharmaceutical compns. are also provided.

L27 ANSWER 31 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:594903 HCAPLUS
DOCUMENT NUMBER: 131:209138
TITLE: Prophylaxis and treatment of migraine headaches with thromboxane synthetase inhibitors and/or receptor antagonists
INVENTOR(S): Plachetka, John R.
PATENT ASSIGNEE(S): Pozen Inc., USA
SOURCE: PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9945905	A2	19990916	WO 1999-US4650	19990311
WO 9945905	A3	19991021		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

AU 9928908 A 19990927 AU 1999-28908 19990311
PRIORITY APPLN. INFO.: US 1998-78001P P 19980313
WO 1999-US4650 W 19990311

AB The use of thromboxane receptor antagonists and/or thromboxane synthetase inhibitors in the prophylaxis and treatment of migraine is described. Further described are the use of thromboxane receptor antagonists and/or thromboxane synthetase inhibitors together with known migraine palliatives such as 5-HT1 agonists, non-steroidal anti-inflammatory agents, and the like. Pharmaceutical compns. are described containing both known migraine palliatives and thromboxane receptor antagonists and/or thromboxane synthetase inhibitors.

L27 ANSWER 32 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:119824 HCAPLUS
DOCUMENT NUMBER: 130:134196
TITLE: Formulation of 5-HT
agonist and NSAID for treatment of
migraine
INVENTOR(S): Plachetka, John R.
PATENT ASSIGNEE(S): Pozen, Inc., USA
SOURCE: U.S., 9 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5872145	A	19990216	US 1997-907826	19970814
CA 2260943	A1	19980219	CA 1997-2260943	19970815
CA 2260943	C	20061107		
EP 957914	A1	19991124	EP 1997-937297	19970815
EP 957914	B1	20050105		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2000506541	T	20000530	JP 1998-510092	19970815
JP 3712420	B2	20051102		
JP 2002255855	A	20020911	JP 2002-17771	19970815
AT 286393	T	20050115	AT 1997-937297	19970815
PT 957914	T	20050429	PT 1997-937297	19970815
ES 2234025	T3	20050616	ES 1997-937297	19970815
US 6060499	A	20000509	US 1998-151912	19980911
US 6586458	B1	20030701	US 2000-559753	20000427
HK 1023517	A1	20050422	HK 2001-102812	20000510
US 2003232876	A1	20031218	US 2003-414493	20030416
JP 2005325143	A	20051124	JP 2005-236180	20050816
PRIORITY APPLN. INFO.:				US 1996-24129P P 19960816
				US 1997-907826 A 19970814
				JP 1998-510092 A3 19970815
				JP 2002-17771 A3 19970815
				WO 1997-US14461 W 19970815
				US 1998-151912 A2 19980911
				US 1999-253278 B2 19990219
				US 2000-559753 A2 20000427

AB A method of treating migraine in a human comprises co-timely administering of a therapeutically effective amount of a 5-HT agonist coordinated with a therapeutically effective amount of an analgesic, particularly a long-acting NSAID in doses below those ordinarily considered as min. EDs as to both 5-HT agonist and long-acting NSAID. Dosage forms are also included.

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 33 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1999:354535 HCAPLUS
 DOCUMENT NUMBER: 131:27400
 TITLE: Pharmaceuticals for treatment of
 migraine headache
 AUTHOR(S): Uematsu, Kazuko
 CORPORATE SOURCE: Dep. Pharm., Japanese Res. Cross Med. Cent., Japan
 SOURCE: Farumashia (1999), 35(6), 580-582
 CODEN: FARUAW; ISSN: 0014-8601
 PUBLISHER: Pharmaceutical Society of Japan
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: Japanese
 AB A review with 14 refs., on the pathol. state and mechanism of
 migraine headache, involvement of serotonin in migraine
 headache, and antimigraine drugs including sumatriptan, a 5HT1D
 agonist.

L27 ANSWER 34 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1998:197492 HCAPLUS
 DOCUMENT NUMBER: 128:244050
 TITLE: Preparation of imidazoles with serotonin receptor
 binding activity
 INVENTOR(S): Glennon, Richard A.; Law, Ho
 PATENT ASSIGNEE(S): Allelix Biopharmaceuticals Inc., Can.; Virginia
 Commonwealth University
 SOURCE: PCT Int. Appl., 29 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9812183	A1	19980326	WO 1997-CA680	19970917
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 5969137	A	19991019	US 1997-821297	19970320
AU 9742918	A	19980414	AU 1997-42918	19970917
PRIORITY APPLN. INFO.:			US 1996-715792	A 19960919
			US 1997-821297	A 19970320
			WO 1997-CA680	W 19970917

OTHER SOURCE(S): MARPAT 128:244050
 AB The title compds. [I; R1 = H, C1-6 alkyl, PhCH2; R2, R3 = H, C1-6 alkyl; R4 = C1-6 alkyl, halo; R5 = H, OH; when R1 = H and R2 = R3 = Me then R4 ≠ Me3C] and their salts, solvates or hydrates, 5-HT1D receptor agonists useful in the treatment of CNS conditions, especially migraine, are claimed. Also claimed are pharmaceutical compns. containing I. For example, I (R1 = R5 = H, R2 = R3 = Me, R4 = Br) prepared by cyclocondensation of H2NCH2CH2NH2 with 4,2,6-BrMe2C6H2CH2C(:NH)OEt (obtained from 4,2,6-BrMe2C6H2CHO via benzyl alc. -> chloride -> nitrile -> acetimidate route) in vitro caused 50% of the maximum contraction of a rabbit isolated saphenous vein with EC50 9.3 mM, vs. 0.22 for sumatriptan.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 35 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:161126 HCAPLUS
 DOCUMENT NUMBER: 128:204796
 TITLE: Substituted 1,2,3,4-tetrahydro-2-dibenzofuranamines and 2-aminocyclohepta[b]benzofurans as 5-HT1F agonists
 INVENTOR(S): Flaugh, Michael E.; Kiefer, Anton D., Jr.
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 86 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9808502	A1	19980305	WO 1997-US14938	19970825
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2264267	A1	19980305	CA 1997-2264267	19970825
AU 9740880	A	19980319	AU 1997-40880	19970825
AU 741324	B2	20011129		
EP 929299	A1	19990721	EP 1997-938585	19970825
EP 929299	B1	20031008		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
BR 9711273	A	19990817	BR 1997-11273	19970825
CN 1228695	A	19990915	CN 1997-197483	19970825
HU 9902901	A2	20000528	HU 1999-2901	19970825
NZ 334031	A	20000728	NZ 1997-334031	19970825
JP 2000516957	T	20001219	JP 1998-511794	19970825
IL 128500	A	20030624	IL 1997-128500	19970825
AT 251457	T	20031015	AT 1997-938585	19970825
PT 929299	T	20040227	PT 1997-938585	19970825
ES 2208948	T3	20040616	ES 1997-938585	19970825
MX 9901756	A	20000831	MX 1999-1756	19990222
NO 9900849	A	19990223	NO 1999-849	19990223
KR 2000035942	A	20000626	KR 1999-701683	19990227
PRIORITY APPLN. INFO.:				US 1996-24745P P 19960828
				WO 1997-US14938 W 19970825

OTHER SOURCE(S): CASREACT 128:204796; MARPAT 128:204796
 AB The invention provides substituted-2-amino-1,2,3,4-tetrahydrodibenzofurans and 2-aminocyclohepta[b]benzofurans useful as 5-HT1F agonists. Claimed compds. are I [R1, R2 = H, C1-4 alkyl, benzyl, α -methyl-4-nitrobenzyl; X = NO2, halo, OH, NH2, -CN, NHC(O)R3, C(O)R6, NHSO2R7, SO2NHR10; R3 = C1-6 alkyl, C2-6 alkenyl, C3-8 cycloalkyl, (un)substituted Ph, naphthyl, phenyl(C1-4 alkylene), thienylmethyl, heterocyclyl; R6 = OH, amino, C1-6 alkoxy, PhCH2O, PhO, NHR8; R7, R10 = C1-6 alkyl, Ph (un)substituted with one halo or C1-4 alkyl group; R8 = C1-6 alkyl, C2-6 alkenyl, C3-8 cycloalkyl, (un)substituted Ph, naphthyl, heterocyclyl; m = 1, 2] and their pharmaceutically acceptable salts. Pharmaceutical formulations of I are also claimed (2 examples). To demonstrate the use of compds. I in the treatment of migraine, their ability to bind to the 5-HT1F receptor subtype was determined. All compds. I tested exhibited an IC50 at the 5-HT1F receptor of $\geq 5 \mu\text{mol}$.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

DOCUMENT NUMBER: 128:145352
 TITLE: Inclusion complex containing indole selective serotonin agonist
 INVENTOR(S): Penkler, Lawrence John; De Kock, Lueta-Ann; Whittaker, Darryl Vanstone
 PATENT ASSIGNEE(S): Farmarc Nederland B.V., Neth.; Dyer, Alison, Margaret
 SOURCE: PCT Int. Appl., 29 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9802186	A1	19980122	WO 1997-GB1872	19970711
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2257860	A1	19980122	CA 1997-2257860	19970711
CA 2259418	A1	19980122	CA 1997-2259418	19970711
ZA 9706178	A	19980203	ZA 1997-6178	19970711
ZA 9706179	A	19980203	ZA 1997-6179	19970711
AU 9734551	A	19980209	AU 1997-34551	19970711
AU 712546	B2	19991111		
CN 1225018	A	19990804	CN 1997-196294	19970711
BR 9710241	A	19990810	BR 1997-10241	19970711
CN 1230123	A	19990929	CN 1997-197767	19970711
JP 2000505090	T	20000425	JP 1998-505725	19970711
KR 2000022239	A	20000425	KR 1998-710659	19981226
KR 2000023708	A	20000425	KR 1999-700167	19990111
PRIORITY APPLN. INFO.:			ZA 1996-5889	A 19960711
			WO 1997-GB1872	W 19970711

AB An inclusion complex comprises (a) an indole selective serotonin (5-HT_{1D}) agonist or a pharmaceutically acceptable salt thereof, for example sumatriptan, and (b) unsubstituted or substituted β - or γ -cyclodextrin, for example Me β -cyclodextrin. Pharmaceutical compns. containing the inclusion complex and the use of the inclusion complex in the treatment of migraine and cluster headaches are also disclosed. A sumatriptan succinate-Me β -cyclodextrin complex was prepared

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 37 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1999:142613 HCAPLUS
 DOCUMENT NUMBER: 130:158398
 TITLE: Pharmaceutical formulations comprising a 5-HT agonist and an anti-emetic and/or gastro-prokinetic agent
 INVENTOR(S): Hargreaves, Richard John
 PATENT ASSIGNEE(S): Merck Sharp and Dohme Limited, UK
 SOURCE: Brit. UK Pat. Appl., 8 pp.
 CODEN: BAXXDU
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2325161	A	19981118	GB 1998-9556	19980505
PRIORITY APPLN. INFO.:			GB 1997-9739	A 19970514

AB Pharmaceutical formulations comprising a 5-HT_{1B/1D} agonist, e.g. rizatriptan, in combination with an anti-emetic and/or gastro-prokinetic agent, e.g. metoclopramide, are used for sep. or sequential use in the control of migraine-associated nausea and vomiting. A tablet contained rizatriptan benzoate 5.0, metoclopramide hydrochloride 10.0, modified corn starch 42.0, microcryst. cellulose 42.0, and magnesium stearate 1.0 mg.

L27 ANSWER 38 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1998:621759 HCAPLUS
 DOCUMENT NUMBER: 129:207208
 TITLE: Treatment of migraine
 INVENTOR(S): Sandquist, Eric; Simitchieva, Kremena S.
 PATENT ASSIGNEE(S): Merck and Co., Inc., USA
 SOURCE: Brit. UK Pat. Appl., 25 pp.
 CODEN: BAXXDU
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2315673	A	19980211	GB 1997-15490	19970723
PRIORITY APPLN. INFO.:			US 1996-22899P	P 19960801
			GB 1996-17896	A 19960828

AB A pharmaceutical composition for the treatment of migraine comprises an effective amount of a local anesthetic and a 5-HT_{1D} agonist. The local anesthetic is preferably benzocaine, mepivacaine, bupivacaine, cocaine, lidocaine, or prilocaine, while the agonist may be rizatriptan, sumatriptan, naratriptan, or zolmitriptan. The composition is preferably in a form for intranasal administration.

L27 ANSWER 39 OF 39 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1997:145241 HCAPLUS
 DOCUMENT NUMBER: 126:157395
 TITLE: Process for parallel synthesis of a non-peptide library
 INVENTOR(S): Fritz, James E.; Kaldor, Stephen W.
 PATENT ASSIGNEE(S): Eli Lilly and Co., USA; Fritz, James E.; Kaldor, Stephen W.
 SOURCE: PCT Int. Appl., 59 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9700244	A1	19970103	WO 1996-US10454	19960617
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM				
AU 9663861	A	19970115	AU 1996-63861	19960617
PRIORITY APPLN. INFO.:			US 1995-310P	P 19950619
			US 1995-492277	A2 19950619

OTHER SOURCE(S): CASREACT 126:157395; MARPAT 126:157395

AB A process for the sequential preparation of a library of compds. having pharmaceutical usage is claimed. The process is specifically applicable to indole derivs. R2N(A)XR1 [I; wherein A = indole analog; X = bond, CO, CS; R1 = H, alkyl, aryl, cycloalkyl, heterocyclyl, NR3R4, or OR5; R2, R3, R4 = H, alkyl, aryl, cycloalkyl, heterocyclyl, or their substituted analogs; R1 ≠ R2 when X = bond; R5 = H, alkyl, aryl, cycloalkyl, or their substituted analogs]. The process involves the sequential mixing of solution phase reagents, followed by scavenging of excess unreacted reagents with solid phase scavenging agents. The process is highly iterative and applicable to production of various ureas, thioureas, amides, carbonates and tertiary amines. For example, 5-amino-3-(1-methylpiperidin-4-yl)-1H-indole reacted with ClCOEt in CH2Cl2 in the presence of polyvinylpyridine at room temperature for 2 days. The mixture was treated with aminomethylated polystyrene for 18 h and evaporated to give 84% title compound II. Over 50 compds. I were prepared. In selectivity tests against 4 serotonin receptor subtypes, II had a Ki value of 2.8 nM at 5-HT1F receptors, vs. 6.1 nM at 5-HT1A, 38.3 nM at 5-HT1Dα, and 182.8 nM at 5-HT1Dβ receptors. A study of sumatriptan succinate and 4 other compds. at 4 receptor subtypes is also described, with the binding at 5-HT1F receptors showing a 0.94 correlation factor to inhibition of protein extravasation.

=> d his

(FILE 'HOME' ENTERED AT 09:00:02 ON 22 AUG 2007)

FILE 'MEDLINE, EMBASE, BIOSIS, BIOTECHDS, SCISEARCH, HCAPLUS, NTIS, LIFESCI' ENTERED AT 09:00:33 ON 22 AUG 2007

```

L1      159646 S "5-HT"
L2      8299 S L1 (W) (AGONIST? OR STIMULAT? OR ENHANC?)
L3      81995 S MIGRAINE
L4      461 S L2 AND L3
L5      14302 S SUMATRIPTAN?
L6      192 S L4 AND L5
L7      42565 S MICROPARTICL?
L8      1 S L6 AND L7
L9      1 S L5 (W) L7
L10     192 S L4 AND L5
L11     39 S PHARMACEUTICAL AND L10
L12     73 S GLYCERYL (W) PALMITOSTEARATE?
L13     1 S L11 AND L12
L14     4 S L2 AND L7
L15     4 DUP REM L14 (0 DUPLICATES REMOVED)
L16     0 S TRIPTAN AND L12
L17     181 DUP REM L6 (11 DUPLICATES REMOVED)
L18     1 S L12 AND L17
L19     1 S L17 AND SPHERONIZ?
L20     1 S L17 AND (MACROGOL (3W) ESTER)
        E MEZAACHE N/AU
L21     2 S E4
        E MEZAACHE D/AU
L22     5 S E4-E5
        E FRISBEE S/AU
L23     94 S E3-E12
        E MAES P/AU
L24     360 S E3
L25     458 S L21 OR L22 OR L23 OR L24
L26     1 S L3 AND L25
L27     39 DUP REM L11 (0 DUPLICATES REMOVED)

```

=> s l27 and l7

L28

1 L27 AND L7

=> d ibib

L28 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:681407 HCAPLUS
 DOCUMENT NUMBER: 141:195316
 TITLE: Rapid absorption selective 5-HT
 agonist formulations
 INVENTOR(S): Mezaache, Naima; Mezaache, Djelila; Frisbee, Steve;
 Maes, Paul
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 45 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004162333	A1	20040819	US 2004-779784	20040218
AU 2004212976	A1	20040902	AU 2004-212976	20040218
CA 2514875	A1	20040902	CA 2004-2514875	20040218
WO 2004073632	A2	20040902	WO 2004-US4572	20040218
WO 2004073632	A3	20041118		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1594470	A2	20051116	EP 2004-712297	20040218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006523620	T	20061019	JP 2006-503623	20040218
MX 2005PA08838	A	20060217	MX 2005-PA8838	20050819
NO 2005004015	A	20050916	NO 2005-4015	20050830
PRIORITY APPLN. INFO.:			US 2003-447741P	P 20030219
			WO 2004-US4572	W 20040218

=> d his

(FILE 'HOME' ENTERED AT 09:00:02 ON 22 AUG 2007)

FILE 'MEDLINE, EMBASE, BIOSIS, BIOTECHDS, SCISEARCH, HCAPLUS, NTIS,
 LIFESCI' ENTERED AT 09:00:33 ON 22 AUG 2007

L1 159646 S "5-HT"
 L2 8299 S L1 (W) (AGONIST? OR STIMULAT? OR ENHANC?)
 L3 81995 S MIGRAINE
 L4 461 S L2 AND L3
 L5 14302 S SUMATRIPTAN?
 L6 192 S L4 AND L5
 L7 42565 S MICROPARTICL?
 L8 1 S L6 AND L7
 L9 1 S L5 (W) L7
 L10 192 S L4 AND L5
 L11 39 S PHARMACEUTICAL AND L10
 L12 73 S GLYCERYL (W) PALMITOSTEARATE?
 L13 1 S L11 AND L12
 L14 4 S L2 AND L7

L15 4 DUP REM L14 (0 DUPLICATES REMOVED)
 L16 0 S TRIPTAN AND L12
 L17 181 DUP REM L6 (11 DUPLICATES REMOVED)
 L18 1 S L12 AND L17
 L19 1 S L17 AND SPHERONIZ?
 L20 1 S L17 AND (MACROGOL (3W)ESTER)
 E MEZAACHE N/AU
 L21 2 S E4
 E MEZAACHE D/AU
 L22 5 S E4-E5
 E FRISBEE S/AU
 L23 94 S E3-E12
 E MAES P/AU
 L24 360 S E3
 L25 458 S L21 OR L22 OR L23 OR L24
 L26 1 S L3 AND L25
 L27 39 DUP REM L11 (0 DUPLICATES REMOVED)
 L28 1 S L27 AND L7

=> s sheroniz? and l27

L29 0 SHERONIZ? AND L27

=> s spheroniz? and l27

L30 1 SPHERONIZ? AND L27

=> d ibib

L30 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:681407 HCAPLUS

DOCUMENT NUMBER: 141:195316

TITLE: Rapid absorption selective 5-HT
agonist formulations

INVENTOR(S): Mezaache, Naima; Mezaache, Djelila; Frisbee, Steve;
Maes, Paul

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 45 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004162333	A1	20040819	US 2004-779784	20040218
AU 2004212976	A1	20040902	AU 2004-212976	20040218
CA 2514875	A1	20040902	CA 2004-2514875	20040218
WO 2004073632	A2	20040902	WO 2004-US4572	20040218
WO 2004073632	A3	20041118		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1594470	A2	20051116	EP 2004-712297	20040218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006523620	T	20061019	JP 2006-503623	20040218
MX 2005PA08838	A	20060217	MX 2005-PA8838	20050819
NO 2005004015	A	20050916	NO 2005-4015	20050830
PRIORITY APPLN. INFO.:			US 2003-447741P	P 20030219

=>

=> d his

(FILE 'HOME' ENTERED AT 09:00:02 ON 22 AUG 2007)

FILE 'MEDLINE, EMBASE, BIOSIS, BIOTECHDS, SCISEARCH, HCAPLUS, NTIS, LIFESCI' ENTERED AT 09:00:33 ON 22 AUG 2007

L1 159646 S "5-HT"
L2 8299 S L1 (W) (AGONIST? OR STIMULAT? OR ENHANC?)
L3 81995 S MIGRAINE
L4 461 S L2 AND L3
L5 14302 S SUMATRIPTAN?
L6 192 S L4 AND L5
L7 42565 S MICROPARTICL?
L8 1 S L6 AND L7
L9 1 S L5 (W) L7
L10 192 S L4 AND L5
L11 39 S PHARMACEUTICAL AND L10
L12 73 S GLYCERYL (W) PALMITOSTEARATE?
L13 1 S L11 AND L12
L14 4 S L2 AND L7
L15 4 DUP REM L14 (0 DUPLICATES REMOVED)
L16 0 S TRIPTAN AND L12
L17 181 DUP REM L6 (11 DUPLICATES REMOVED)
L18 1 S L12 AND L17
L19 1 S L17 AND SPHERONIZ?
L20 1 S L17 AND (MACROGOL (3W) ESTER)
E MEZAACHE N/AU
L21 2 S E4
E MEZAACHE D/AU
L22 5 S E4-E5
E FRISBEE S/AU
L23 94 S E3-E12
E MAES P/AU
L24 360 S E3
L25 458 S L21 OR L22 OR L23 OR L24
L26 1 S L3 AND L25
L27 39 DUP REM L11 (0 DUPLICATES REMOVED)
L28 1 S L27 AND L7
L29 0 S SPHERONIZ? AND L27
L30 1 S SPHERONIZ? AND L27

	Document ID	Kind Codes	Source	Issue Date	Page s	Title
1	US 2004016233 3 A1		US- PGPUB	20040819	45	Rapid absorption selective 5-HT agonist formulations

	Document ID	Kind Codes	Source	Issue Date	Pages	Title
1	US 2007019146 2 A1		US- PGPUB	20070816	16	Combination of A 5-HT(1) Receptor Agonist and an Alpha-2-Delta Ligand for the Treatment of Migraine
2	US 2007008800 5 A1		US- PGPUB	20070419	14	PHARMACEUTICAL COMPOSITIONS FOR HEADACHE, MIGRAINE, NAUSEA AND EMESIS
3	US 2005018720 5 A1		US- PGPUB	20050825	19	Pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorders
4	US 2004021486 1 A1		US- PGPUB	20041028	54	Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine
5	US 2004016233 3 A1		US- PGPUB	20040819	45	Rapid absorption selective 5-HT agonist formulations
6	US 2004000604 4 A1		US- PGPUB	20040108	16	Pharmaceutical compositions for headache, migraine, nausea and emesis
7	US 2003023287 6 A1		US- PGPUB	20031218	12	Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
8	US 7148208 B2		USPAT	20061212	14	Pharmaceutical compositions for headache, migraine, nausea and emesis
9	US 6903130 B1		USPAT	20050607	16	Pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders

	Document ID	Kind Codes	Source	Issue Date	Pages	Title
10	US 6586458 B1		USPAT	20030701	10	Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs

	Document ID	Kind Codes	Source	Issue Date	Pages	Title
1	US 2007019146 2 A1		US- PGPUB	20070816	16	Combination of A 5-HT(1) Receptor Agonist and an Alpha-2-Delta Ligand for the Treatment of Migraine
2	US 2007008800 5 A1		US- PGPUB	20070419	14	PHARMACEUTICAL COMPOSITIONS FOR HEADACHE, MIGRAINE, NAUSEA AND EMESIS
3	US 2005018720 5 A1		US- PGPUB	20050825	19	Pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorders
4	US 2004021486 1 A1		US- PGPUB	20041028	54	Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine
5	US 2004016233 3 A1		US- PGPUB	20040819	45	Rapid absorption selective 5-HT agonist formulations
6	US 2004000604 4 A1		US- PGPUB	20040108	16	Pharmaceutical compositions for headache, migraine, nausea and emesis
7	US 2003023287 6 A1		US- PGPUB	20031218	12	Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
8	US 7148208 B2		USPAT	20061212	14	Pharmaceutical compositions for headache, migraine, nausea and emesis
9	US 6903130 B1		USPAT	20050607	16	Pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders

	Document ID	Kind Codes	Source	Issue Date	Pages	Title
1	US 2007019146 2 A1		US- PGPUB	20070816	16	Combination of A 5-HT(1) Receptor Agonist and an Alpha-2-Delta Ligand for the Treatment of Migraine
2	US 2007018410 9 A1		US- PGPUB	20070809	17	Compositions comprising triptans and nsaids
3	US 2007017919 5 A1		US- PGPUB	20070802	24	Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
4	US 2007015573 4 A1		US- PGPUB	20070705	56	Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
5	US 2007012928 3 A1		US- PGPUB	20070607	18	Compositions and methods for reducing food cravings
6	US 2007011782 7 A1		US- PGPUB	20070524	19	Compositions for affecting weight loss
7	US 2007008800 5 A1		US- PGPUB	20070419	14	PHARMACEUTICAL COMPOSITIONS FOR HEADACHE, MIGRAINE, NAUSEA AND EMESIS
8	US 2007008194 9 A1		US- PGPUB	20070412	14	Buccal drug delivery
9	US 2007006057 1 A1		US- PGPUB	20070315	70	Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use

	Document ID	Kind Codes	Source	Issue Date	Pages	Title
10	US 2007005925 4 A1		US- PGPUB	20070315	30	Compositions for delivering 5-HT agonists across the oral mucosa and methods of use thereof
11	US 2007003251 7 A1		US- PGPUB	20070208	67	Substituted naphthyridinone derivatives
12	US 2007002731 0 A1		US- PGPUB	20070201	43	Novel ligands and methods for preparing same
13	US 2007000474 2 A1		US- PGPUB	20070104	60	Arylpiperazinyl compounds
14	US 2006019486 1 A1		US- PGPUB	20060831	56	Cyclooxygenase-2 selective inhibitors, compositions and methods of use
15	US 2006014229 0 A1		US- PGPUB	20060629	23	Compositions for affecting weight loss
16	US 2006013551 1 A1		US- PGPUB	20060622	33	Benzodiazepine cgrp receptor antagonists
17	US 2006012747 9 A1		US- PGPUB	20060615	9	Solvent free taste masked pharmaceutical compositions
18	US 2006008480 5 A1		US- PGPUB	20060420	30	Synthesis of thienopyridinone compounds and related intermediates
19	US 2006007954 7 A1		US- PGPUB	20060413	19	Thienopyridinone compounds and methods of treatment
20	US 2006005829 3 A1		US- PGPUB	20060316	15	Combination of bupropion and a second compound for affecting weight loss

	Document ID	Kind Codes	Source	Issue Date	Pages	Title
21	US 2006000944 8 A1		US- PGPUB	20060112	24	Metabolites of 4-(3,4-dichlorophenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]thiomorpholin-3-one
22	US 2005028830 4 A1		US- PGPUB	20051229	37	Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists
23	US 2005025615 3 A1		US- PGPUB	20051117	30	Thienopyridinone compounds and methods of treatment
24	US 2005022224 3 A1		US- PGPUB	20051006	58	Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
25	US 2005022217 5 A1		US- PGPUB	20051006	73	New piperidinylamino-thieno[2,3-D]pyrimidine compounds
26	US 2005005966 5 A1		US- PGPUB	20050317	54	Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use
27	US 2005004228 1 A1		US- PGPUB	20050224	18	Compositions for delivering therapeutic agents across the oral mucosa
28	US 2004025420 8 A1		US- PGPUB	20041216	24	Compositions for affecting weight loss
29	US 2004024890 4 A1		US- PGPUB	20041209	61	New piperidinylamino-thieno[2,3-d]pyrimidine compounds
30	US 2004022019 2 A1		US- PGPUB	20041104	61	Arylpiperazinyl compounds

	Document ID	Kind Codes	Source	Issue Date	Pages	Title
31	US 2004021486 1 A1		US- PGPUB	20041028	54	Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT _{1B} 1D antagonists for the treatment and prevention of migraine
32	US 2004020449 5 A1		US- PGPUB	20041014	11	Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment of prevention of pain and/or headache disorders
33	US 2004019117 8 A1		US- PGPUB	20040930	13	Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
34	US 2004017633 1 A1		US- PGPUB	20040909	19	Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors
35	US 2004016233 3 A1		US- PGPUB	20040819	45	Rapid absorption selective 5-HT agonist formulations
36	US 2004013298 1 A1		US- PGPUB	20040708	43	Novel ligands and methods for preparing same
37	US 2004011643 1 A1		US- PGPUB	20040617	55	Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use

	Document ID	Kind Codes	Source	Issue Date	Pages	Title
38	US 2004007289 9 A1		US- PGPUB	20040415	27	Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
39	US 2004007288 3 A1		US- PGPUB	20040415	57	Cyclooxygenase-2 selective inhibitors, compositions and methods of use
40	US 2004005398 5 A1		US- PGPUB	20040318	57	Cyclooxygenase-2 selective inhibitors, compositions and methods of use
41	US 2004002405 7 A1		US- PGPUB	20040205	69	Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use related applications
42	US 2004000613 3 A1		US- PGPUB	20040108	74	Oxime and/or hydrozone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
43	US 2004000604 4 A1		US- PGPUB	20040108	16	Pharmaceutical compositions for headache, migraine, nausea and emesis
44	US 2003023287 6 A1		US- PGPUB	20031218	12	Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs

45	US 2003022022 8 A1		US- PGPUB	20031127	71	Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
----	--------------------------	--	--------------	----------	----	---

	Document ID	Kind Codes	Source	Issue Date	Pages	Title
46	US 2003021205 0 A1		US- PGPUB	20031113	8	Prophylactic treatment of migraine
47	US 2003019866 9 A1		US- PGPUB	20031023	18	Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
48	US 2003018149 5 A1		US- PGPUB	20030925	31	Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
49	US 2003016606 6 A1		US- PGPUB	20030904	45	DNA encoding a human serotonin receptor (5-HT4B) and uses thereof
50	US 2003010863 0 A1		US- PGPUB	20030612	12	Morinda citrifolia enhanced nutraceutical formulation and method for treating and preventing migraine headaches
51	US 2003002291 0 A1		US- PGPUB	20030130	14	Compositions and methods for sublingual formulations of dihydroergotamine for the treatment of migraine
52	US 2003001799 4 A1		US- PGPUB	20030123	13	Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
53	US 2003001717 5 A1		US- PGPUB	20030123	12	Sublingual administration of dihydroergotamine for the treatment of migraine

	Document ID	Kind Codes	Source	Issue Date	Pages	Title
54	US 2003000800 5 A1		US- PGPUB	20030109	8	Sublingual administration of dihydroergotamine for the treatment of migraine
55	US 2002018336 6 A1		US- PGPUB	20021205	42	Cyclooxygenase-2 inhibitors, compositions and methods of use
56	US 2002015154 0 A1		US- PGPUB	20021017	30	Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
57	US 2002011997 7 A1		US- PGPUB	20020829	57	Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use related applications
58	US 2002009905 9 A1		US- PGPUB	20020725	5	Combination therapy for the treatment of migraine
59	US 2002008166 1 A1		US- PGPUB	20020627	71	DNA encoding 5-HT4 serotonin receptors and uses thereof
60	US 2002004557 3 A1		US- PGPUB	20020418	18	POLYDITHIOCARBAMATE-CONTAINING NON-TARGETING MACROMOLECULES AND THE USE THEREOF FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS
61	US 2002003221 5 A1		US- PGPUB	20020314	18	Azapirone pain treatment
62	US 2001005134 8 A1		US- PGPUB	20011213	43	Novel ligands and methods for preparing same

	Document ID	Kind Codes	Source	Issue Date	Pages	Title
63	US 2001004172 6 A1		US- PGPUB	20011115	88	Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
64	US 2001001658 4 A1		US- PGPUB	20010823	13	Treatment of pain
65	US 7244753 B2		USPAT	20070717	41	Cyclooxygenase-2 selective inhibitors, compositions and methods of use
66	US 7220749 B2		USPAT	20070522	21	Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
67	US 7211598 B2		USPAT	20070501	47	Oxime and/or hydrozone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
68	US 7169809 B2		USPAT	20070130	18	Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors
69	US 7166618 B2		USPAT	20070123	67	Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use

	Document ID	Kind Codes	Source	Issue Date	Pages	Title
70	US 7163958 B2		USPAT	20070116	55	Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
71	US 7153977 B2		USPAT	20061226	42	Ligands and methods for preparing same
72	US 7153858 B2		USPAT	20061226	56	Arylpiperazinyl compounds
73	US 7148208 B2		USPAT	20061212	14	Pharmaceutical compositions for headache, migraine, nausea and emesis
74	US 7087630 B2		USPAT	20060808	51	Cyclooxygenase 2 selective inhibitors, compositions and methods of use
75	US 6825185 B2		USPAT	20041130	50	Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use
76	US 6706724 B2		USPAT	20040316	52	Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use
77	US 6685951 B2		USPAT	20040203	12	Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
78	US 6649629 B2		USPAT	20031118	63	Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use

	Document ID	Kind Codes	Source	Issue Date	Pages	Title
79	US 6649591 B2		USPAT	20031118	18	Polydithiocarbamate-containing non-targeting macromolecules and the use thereof for therapeutic and diagnostic applications
80	US 6596770 B2		USPAT	20030722	28	Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
81	US 6589991 B1		USPAT	20030708	29	Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
82	US 6586458 B1		USPAT	20030701	10	Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
83	US 6566361 B2		USPAT	20030520	17	Azapirone pain treatment
84	US 6511982 B2		USPAT	20030128	13	Treatment of pain
85	US 6432655 B1		USPAT	20020813	42	Method of obtaining compositions
86	US 6380226 B1		USPAT	20020430	13	Salts of an anti-migraine indole derivatives
87	US 6376243 B1		USPAT	20020423	42	DNA encoding a human serotonin receptor (5-HT4B) and uses thereof
88	US 6331401 B1		USPAT	20011218	67	Uses of the 5-HT4 receptor
89	US 6316502 B1		USPAT	20011113	29	Therapeutic methods employing disulfide derivatives of dithiocarbonates and compositions useful therefor

	Document ID	Kind Codes	Source	Issue Date	Pages	Title
90	US 6300087 B1		USPAT	20011009	41	DNA encoding a human serotonin receptor (5-HT4B) and uses thereof
91	US 6281357 B1		USPAT	20010828	19	Process for the production of indole derivatives
92	US 6255306 B1		USPAT	20010703	21	4-indole derivatives as serotonin agonists and antagonists
93	US 6255089 B1		USPAT	20010703	85	Constitutively activated serotonin receptors
94	US 6110940 A		USPAT	20000829	13	Salts of an anti-migraine indole derivative
95	US 6093822 A		USPAT	20000725	8	5-arylindole derivatives
96	US 6093743 A		USPAT	20000725	29	Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
97	US 6083749 A		USPAT	20000704	38	DNA encoding a human serotonin receptor (5-HT.sub.4B) and uses thereof
98	US 6060499 A		USPAT	20000509	10	Anti-migraine methods and compositions using 5-HT agonists with long-acting NSAIDs
99	US 6043244 A		USPAT	20000328	6	Method and composition for treating migraine
100	US 5994352 A		USPAT	19991130	8	5-arylindole derivatives
101	US 5985585 A		USPAT	19991116	43	Processes using a human serotonin receptor (5-HT.sub.4B)
102	US 5968817 A		USPAT	19991019	70	DNA encoding serotonin receptors

103	US 5942524 A		USPAT	19990824	8	5-arylindole derivatives
-----	-----------------	--	-------	----------	---	-----------------------------

	Document ID	Kind Codes	Source	Issue Date	Pages	Title
104	US 5939425 A		USPAT	19990817	6	Method for treating a migraine
105	US 5891885 A		USPAT	19990406	6	Method for treating migraine
106	US 5872145 A		USPAT	19990216	9	Formulation of 5-HT agonist and NSAID for treatment of migraine
107	US 5849739 A		USPAT	19981215	8	5-arylindole derivatives
108	US 5785989 A		USPAT	19980728	17	Compositions and methods of manufacturing of oral dissolvable medicaments
109	US 5766879 A		USPAT	19980616	66	DNA encoding 5-HT.sub.4 serotonin receptors and uses thereof
110	US 5521183 A		USPAT	19960528	7	Use of 5-HT ligands as anti-pruritic agents
111	US 5472866 A		USPAT	19951205	44	DNA encoding 5-HT.sub.4A serotonin receptors
112	US 5436246 A		USPAT	19950725	35	Serotonin receptor agents
113	US 5288498 A		USPAT	19940222	22	Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
114	US 5288497 A		USPAT	19940222	24	Compositions of oral dissolvable medicaments

	L #	Hits	Search Text
1	L1	1	"6117452".pn.
2	L6	1105	palmitostearate
3	L7	5	l1 or l2 or l3 or l4 or l5
4	L8	0	l6 same l7
5	L9	170	macrogol adj3 ester\$2
6	L10	0	l7 same l9
7	L2	1	"6013280".pn.
8	L3	1	"6048541".pn.
9	L4	1	"6270804".pn.
10	L5	1	"6077822".pn.
11	L11	305	5-HT adj agonist\$2
12	L12	82	5-HT adj (stimulat\$3 or enhancer)
13	L13	382	l11 or l12
14	L14	2221	sumatriptan
15	L16	1105	palmitostearate
16	L17	3	l15 and l16
17	L18	1733 07	stearat\$3
18	L19	3	l15 and l17
19	L20	10	triptan and l13
20	L21	1689 34	sheroniz\$3 or stearate
21	L22	1689 33	shperoniz\$3 or stearate
22	L23	1693 87	spheroniz\$3 or stearate
23	L24	9	l20 and l23
24	L25	174	glycerol adj palmitostearate
25	L26	0	triptan and l25
26	L27	0	l13 and l25
27	L28	0	macrigo adj3 ester\$2
28	L29	170	macrogol adj3 ester\$2
29	L30	1	l20 and l29
30	L31	2782	MEZAACHE MEZAACHE- DJELILA MEZAACHE- NAIMA FRISBEE MAES
31	L32	1	l13 and l31

32	L15	114	113 and 114
----	-----	-----	-------------

	L #	Hits	Search Text
1	L1	1	"6117452".pn.
2	L6	1105	palmitostearate
3	L7	5	l1 or l2 or l3 or l4 or l5
4	L8	0	l6 same l7
5	L9	170	macrogol adj3 ester\$2
6	L10	0	l7 same l9
7	L2	1	"6013280".pn.
8	L3	1	"6048541".pn.
9	L4	1	"6270804".pn.
10	L5	1	"6077822".pn.
11	L11	305	5-HT adj agonist\$2
12	L12	82	5-HT adj (stimulat\$3 or enhancer)
13	L13	382	l11 or l12
14	L14	2221	sumatriptan
15	L16	1105	palmitostearate
16	L17	3	l15 and l16
17	L18	1733 07	stearat\$3
18	L19	3	l15 and l17
19	L20	10	triptan and l13
20	L21	1689 34	sheroniz\$3 or stearate
21	L22	1689 33	shperoniz\$3 or stearate
22	L23	1693 87	spheroniz\$3 or stearate
23	L24	9	l20 and l23
24	L25	174	glycerol adj palmitostearate
25	L26	0	triptan and l25
26	L27	0	l13 and l25
27	L28	0	macrigo adj3 ester\$2
28	L29	170	macrogol adj3 ester\$2
29	L30	1	l20 and l29
30	L31	2782	MEZAACHE MEZAACHE- DJELILA MEZAACHE- NAIMA FRISBEE MAES
31	L32	1	l13 and l31

32	L15	114	113 and 114
----	-----	-----	-------------

	L #	Hits	Search Text
1	L1	1	"6117452".pn.
2	L6	1105	palmitostearate
3	L7	5	l1 or l2 or l3 or l4 or l5
4	L8	0	l6 same l7
5	L9	170	macrogol adj3 ester\$2
6	L10	0	l7 same l9
7	L2	1	"6013280".pn.
8	L3	1	"6048541".pn.
9	L4	1	"6270804".pn.
10	L5	1	"6077822".pn.
11	L11	305	5-HT adj agonist\$2
12	L12	82	5-HT adj (stimulat\$3 or enhancer)
13	L13	382	l11 or l12
14	L14	2221	sumatriptan
15	L16	1105	palmitostearate
16	L17	3	l15 and l16
17	L18	1733 07	stearat\$3
18	L19	3	l15 and l17
19	L20	10	triptan and l13
20	L21	1689 34	sheroniz\$3 or stearate
21	L22	1689 33	shperoniz\$3 or stearate
22	L23	1693 87	spheroniz\$3 or stearate
23	L24	9	l20 and l23
24	L25	174	glycerol adj palmitostearate
25	L26	0	triptan and l25
26	L27	0	l13 and l25
27	L28	0	macrigo adj3 ester\$2
28	L29	170	macrogol adj3 ester\$2
29	L30	1	l20 and l29
30	L31	2782	MEZAACHE MEZAACHE- DJELILA MEZAACHE- NAIMA FRISBEE MAES
31	L32	1	l13 and l31

32	L15	114	113 and 114
----	-----	-----	-------------

	L #	Hits	Search Text
33	L33	2757	rapid adj absorption
34	L34	12	l13 and l33
35	L35	1	l29 and l34
36	L36	0	l25 and l34